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Abbreviations 
2xTY rich bacterial medium 
3D three dimensional 
3M6 αHER3 antibody – Seribantumab variable domain with C89S mutation 
4D5 αHER2 antibody – Trastuzumab variable domain/precursor 
A alanine  
a adenine  
aa amino acid 
ADCC antibody-dependent cellular cytotoxicity 
Akt protein kinase B 
ALT alanine aminotransferase 
Amp ampicillin 
APS ammonium persulfate 
AUC area under the curve 
BAD Bcl2-associated death promoter 
BiTE Bispecific T-cell engager 
c cytosine  
C / Cys cysteine 
CDC complement-dependent cytotoxicity 
CDR Complementarity determining region 
CH constant region of the heavy chain 
CL constant region of the light chain 
CR cysteine rich 
CTX cholera toxin 
D aspartic acid  
Da / kDa (kilo) Dalton ((103) g/mol) 
DAPI 4’,6-Diamidin-2-phenylindol 
ddH2O double distilled water 
DI extracellular domain I 
DII extracellular domain II 
DIII extracellular domain III 
DIV extracellular domain IV 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
dox doxycycline 
DTT dithiotreitol 
E glutamic acid  
E.coli Escherichia coli 
e.g. exempli gratia / for example 
EC50 half maximal effective concentration 
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ECD extracellular domain 
ECL enhanced chemiluminescence 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent assay 
ErbB erythroblastic leukemia viral oncogene homolog 
Erk extracellular signal-regulated kinase 
EtOH ethanol 
F phenylalanine  
F(ab)2 antigen binding fragment dimerized via hinge region 
Fab Fragment antigen binding 
FACS Fluorescence activated cell sorting 
Fc Fragment crystallizable 
FCS fetal calf serum 
FDA (U.S.) Food and Drug Administration 
FITC fluorescein isothiocyanate 
g guanine  
G / Gly glycine 
G418 aminoglycoside antibiotic 
Gal12 Galectin 12 (beta-galactoside-binding) 
GDP guanosine diphosphat 
GEF Guanosine exchange factor 
GFP green fluorescent protein 
glc glucose 
Grb2 Growth factor receptor-bound protein 2 
GTP guanosine triphosphat 
h hour 
HB-EGF heparin-binding EGF-like growth factor 
HCl hydrochloric acid 
HEK Human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HER human epidermal receptor 
His histidine 
His6 hexahistidine 
HPLC high performance liquid chromatography 
HRG heregulin 
HRP horseradish peroxidase 
hu human 
I isoleucine  
i.e. id est / that is 
i.p. intraperitoneal 
i.v. intravenous 
IC50 half maximal inhibitory concentration 
IgG immunoglobulin G 
Abbreviations 
8 
IMAC immobilized metal ion affinity chromatography 
IPTG isopropyl-β-D-thiogalactopyranoside 
k kilo (103) 
K lysine  
kb kilo base pairs 
kb kilo base pairs 
kcps Kilo counts per second 
L leucine  
L1 leucine-rich/ligand binding domain 1 
L2 leucine-rich/ligand binding domain 2 
LB lysogeny broth 
m milli (10-3) 
M molar 
M methionine (in amino acid sequences) 
mAb monoclonal antibody 
MAPK mitogen-activated protein kinase 
MEK MAPK/Erk kinase 
MFI mean fluorescence intensity 
MHC Major histocompatibility complex 
mo mouse 
MPBS PBS containing milk powder 
mTOR  mammalian target of rapamycin 
mTORC1 mammalian target of rapamycin complex 1 
mTORC1 mTOR complex 1 
mTORC2 mammalian target of rapamycin complex 2 
MW molecular weight 
n nano (10-9) 
N asparagine  
n.d. not determined 
n/a not applicable 
NaCl  sodium chloride 
NaOH sodium hydroxide 
NFκB nuclear transcription factor kappa B 
NGF Nerve growth factor 
nm nanometer (10-9m) 
NR not reported 
NTA nitrilotriacetic acid 
o/n over night 
OD optical density 
p phospho- (-OPO32-) 
P proline  
P/S penicillin/streptomycin 
PAA Polyacrylamide 
PAGE polyacrylamide gel electrophoresis 
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PBA PBS containing sodium azide 
PBS phosphate buffered saline 
PBST PBS with TWEEN 20 
PCR polymerase chain reaction 
PDGF platelet derived growth factor 
PE phycoerythrin 
PEI polyetylenimine 
PFA Paraformaldehyde 
PH pleckstrin homology 
pH negative decadic logarithm of the H3O+ concentration 
PI propidium iodide 
PI3K phosphatidylinositol 3-kinase 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PIP3 phosphatidylinositol 3,4,5-trisphosphate 
PKD1 Phosphoinositide-dependent protein kinase 1 
PLC phospholipase C 
pM pico molar (10-12 M) 
PPB periplasmic preparation buffer 
PTEN Phosphatase and Tensin homolog 
puro puromycin 
PVDF polyvinylidene difluoride 
Q glutamine  
QCM quarz crystal microbalance 
R arginine  
Raf rapidly accelerated fibrosarcoma 
Ras rat sarcoma 
Rb retinoblastoma 
RIPA radio immune precipitation buffer 
RNA ribonucleic acid 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute 
RSK ribosomal-S6 kinase 
RT room temperature 
RTK receptor tyrosine kinase 
S / Ser serine 
sc single-chain 
scDb single-chain diabody 
scFv single-chain fragment variable 
scTRAIL single-chain TRAIL 
SD standard deviation 
SDS sodium dodecyl sulfate  
Sec size exclusion chromatography 
SH2 Sarc homology 2 
SH3 Sarc homology 3 
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Shc SH2 containing transforming protein C 
SOS son of sevenless 
Src sarcoma 
t thymine  
T / Thr threonine 
t1/2α initial half-life 
t1/2β terminal half-life 
TAA tumor-associated antigen 
TAE tris-acetate-EDTA 
TCEP tris(2-carboxyethyl)phosphine 
TE Tris-EDTA 
TEMED Tetramethylethylenediamine 
Tet tetracycline-inducible 
TGF-α transforming growth factor alpha 
TKI tyrosine kinase inhibitor 
TMB 3,3’,5,5’-Tetramethylbenzidine 
TN1 trypton N1 
TRAIL TNF-related apoptosis-inducing ligand 
Tris tris(hydroxylmethyl)-aminomethane 
UV ultraviolet 
V valine  
v/v  volume by volume 
VEGF vascular epithelial growth factor 
VH variable domain of the heavy chain 
VL variable domain of the light chain 
W tryptophane  
w/o without 
w/v weight per volume 
WB western blot 
Y / Tyr tyrosine 
α anti- 
µ micro (10-6) 
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Abstract 
As conventional anticancer therapeutics often lack specificity and thus lead to 
toxicities to healthy tissues, monoclonal antibodies implicating specific targeting and 
low toxicity profiles have become attractive therapeutic drug candidates. ErbB 
receptors are valuable targets for antibody-mediated tumor therapy. The receptor 
tyrosine kinase (RTK) HER2 is a well-established tumor antigen whose 
overexpression is associated with adverse prognosis in breast cancer. The kinase 
impaired RTK HER3 has only recently emerged as target for antibody-mediated 
tumor therapy. In this study, a panel of scFv selected by phage display from the 
naïve human antibody gene libraries HAL7 and HAL8 were characterized. Two novel 
human monoclonal antibodies, IgG 2-35 and IgG 3-43, were developed from the 
candidates revealing highest affinity to cell surface expressed HER2 and HER3, 
respectively. IgG 2-35 bound to HER2 expressing cancer cells with EC50 values 
between 200 and 330 pM. Furthermore, IgG 2-35 was able to reduce EGF mediated 
proliferation of two HER2 overexpressing cancer cell lines. IgG 3-43 bound to an 
epitope conserved between human and mouse HER3. The bivalent IgG bound 
recombinant bivalent HER3 with subnanomolar affinity (KD = 220 pM) and HER3-
expressing tumor cells with EC50 values in the low picomolar range (3 - 30 pM). The 
antibody competed with heregulin for binding to HER3-expressing cells, efficiently 
inhibited both, heregulin induced and basal phosphorylation of HER3 as well as 
downstream signaling, and induced receptor internalization and degradation. 
Furthermore, IgG 3-43 inhibited heregulin-dependent proliferation of several HER3-
positive cancer cell lines. Inhibition of tumor growth and prolonged survival was 
demonstrated in a FaDu xenograft tumor model in SCID mice. The findings 
demonstrate that IgG 3-43 efficiently blocks activation of HER3, thereby inhibiting 
tumor cell growth both in vitro and in vivo. 
Zusammenfassung 
12 
Zusammenfassung 
Herkömmliche Krebsmedikamente sind oft unspezifisch und greifen daher auch 
gesundes Gewebe an. Monoklonale Antikörper versprechen spezifisches Targeting 
von Tumorzellen und geringe Toxizität, was sie zu attraktiven Kandidaten für 
Tumortherapeutika macht. Rezeptoren der EGFR-Familie sind wertvolle 
Zielstrukturen für die Antikörpervermittelte Tumortherapie. Die Rezeptortyrosinkinase 
HER2 ist ein etabliertes Tumorantigen, dessen Überexpression mit einer schlechten 
Prognose in Brustkrebs assoziiert ist. Die Rezeptortyrosinkinase HER3 wurde 
hingegen, unter anderem aufgrund ihrer eingeschränkten Kinaseaktivität, erst in 
jüngerer Zeit als strategisch wichtiges Tumorantigen bekannt. In der vorliegenden 
Arbeit wurde ein Set an variablen Antikörperdomänen, die zuvor mittels Phage-
display aus einer Antikörpergenbibliothek isoliert wurden, als einzelkettiges variables 
Fragment (scFv) exprimiert und gescreent. Aus den Kandidaten mit den besten 
Bindungseigenschaften zu ihren zellulären Antigenen wurden zwei neuartige humane 
monoklonale Antikörper, IgG 2-35 und IgG 3-43, entwickelt. Die Antikörper wiesen 
hohe Affinität zu HER2 beziehungsweise HER3 auf. IgG 2-35 band HER2-
exprimierende Krebszelllinien mit EC50-Werten zwischen 200 und 330 pM. Zudem 
konnte IgG 2-35 die EGF vermittelte Proliferation in zwei HER2 überexprimierenden 
Krebszelllinien reduzieren. IgG 3-43 erkannte ein Epitop, das bei humanem und 
murinem HER3 konserviert ist. Die Affinität zwischen dem bivalenten Antikörper und 
rekombinantem bivalentem HER3 wurde mittels Quarzkristallmikrowaage-Technik 
gemessen und lag mit einer Dissoziationskonstante von 220 pM im subnanomolaren 
Bereich. HER3 exprimierende Krebszelllinien band IgG 3-43 mit EC50-Werten im 
niederen pikomolaren Bereich (3-30 pM). Der Antikörper konkurrierte mit Heregulin 
um die Bindung von HER3 exprimierenden Zellen, inhibierte die Phosphorylierung 
von HER3 sowie von nachgeschalteten Signalmolekülen, und induzierte die 
Internalisierung und Degradierung des Rezeptors. Zudem inhibierte IgG 3-43 die 
Heregulin-abhängige Proliferation mehrerer HER3-positiven Krebszelllinien. Die 
Inhibierung von Tumorwachstum und ein verlängertes Überleben wurde in einem 
FaDu Xenograft-Modell in SCID-Mäusen nachgewiesen. Die erzielten Ergebnisse 
bestätigen, dass IgG 3-43 in effizienter Weise die Aktivierung von HER3 blockiert 
und dadurch das Wachstum von Tumorzellen sowohl in vitro als auch in vivo 
inhibiert.  
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1 Introduction 
1.1 The EGFR family of receptor tyrosine kinases 
Multicellular organisms depend on growth factors for their development, growth and 
homeostasis. They are required for cell-cell communications underlying embryonic 
tissue induction, fate determination, cell survival, apoptosis, tissue specialization and 
cell migration1. For the transduction of extracellular signals, growth factor receptors 
are needed. For its role in development, physiology, and human cancer, the 
epidermal growth factor (EGF) family of RTKs, also called ErbB or HER receptors, is 
one of the most extensively studied family amongst the receptor tyrosine kinases 
(RTKs)1. 
The majority of growth factor receptors are composed of extracellular, 
transmembrane, and cytoplasmic tyrosine kinase domains2. The ErbB family belongs 
to the type I receptor tyrosine kinases and has four members: EGF receptor, also 
termed ErbB1 or HER1, ErbB2/Neu/HER2, ErbB3/HER3 and ErbB4/HER43. All 
family members share a certain general structure: they comprise a glycosylated 
extracellular (ligand-binding) domain, a single membrane-spanning region and a 
cytoplasmic domain consisting of a juxtamembrane domain, a typical protein tyrosine 
kinase segment, and a tyrosine-rich carboxyterminal tail4,5. Additional regulatory 
sequences in this cytoplasmic domain are subjected to autophosphorylation and 
phosphorylation by heterologous protein kinases6. The extracellular N-terminal 
domain contains four subdomains. The leucine-rich subdomains I (L1) and III (L2) 
directly interact with the ligand. The cysteine-rich subdomain II (CR1) contains the 
dimerization loop responsible for receptor-receptor interaction (reviewed by Wieduwilt 
& Moasser, 2009). Although the four glycoproteins are closely related, some 
important differences exist. The most intriguing one is that ErbB3 has an impaired 
tyrosine kinase activity7. Nonetheless it is noteworthy that, upon trans-
phosphorylation by another ErbB family member, it leads to very potent activation of 
downstream signaling8. EGFR and ErbB4 display fully functional receptors with both, 
the ability to bind ligands and a functional intracellular tyrosine kinase domain1. 
ErbB2 in turn is unique in that it has no known ligand but is the preferred dimerization 
partner for other ErbB receptors1,9,10. The existing differences implicate, that each 
ErbB receptor has a distinct physiological role. Moreover, the physiological 
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characteristics of the four receptors are strongly interdependent, because their 
signaling can be modified by ligand-induced formation of ErbB receptor heterodimers 
or heterooligomers that are capable of generating unique signaling responses11,12. 
ErbB receptors are expressed in epithelial, mesenchymal, and in neuronal cells and 
their progenitors5. Although ErbB receptors are membranous proteins connecting the 
cells to their surroundings, nuclear localization of ErbB receptors has also been 
described13. 
 
A  
 
B  
 
 
 
Figure 1-1: Structural commonalities and differences of ErbB receptors 
A Common structure of ErbB receptors. Residue numbers for domain boundaries are depicted for 
EGFR. In this study, the domains are referred to using the I, II, III, IV nomenclature (Lax et al., 1988b). 
An alternative nomenclature using domain names L1, CR1, L2, CR2 (Ward et al., 1995) is also used in 
the literature. Figure from: Burgess et al. 200314 B Overview of the four ErbB receptors and their most 
prominent differences. The extracellular domain of ErbB2 exhibits an extended conformation, whereas 
ErbB3 has no active kinase domain. Figure from Malm, 201615.  
 
RTKs usually exist as monomers in the cell membrane16. Their activities are 
regulated through ligand-induced hetero- or homooligomerization. Only the binding of 
a ligand induces dimerization of these receptors resulting in autophosphorylation of 
their cytoplasmic domains17. However, this concept induces a somewhat simplified 
view. A more complex view assumes that receptor monomers are in equilibrium with 
receptor dimers. Ligand binding to the extracellular domain stabilizes the formation of 
active dimers and consequently tyrosine kinase stimulation. Schlessinger also 
proposed in 2000, that active dimers can exist even in the absence of ligand 
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binding16. This is reasonable, since autophosphorylation of RTKs can be enhanced in 
the absence of binding ligands by inhibitors of protein tyrosine phosphatases as well 
as by receptor overexpression. The current model for ErbB receptor activation 
suggests, that one kinase domain in a dimer allosterically activates its neighbor and, 
as a consequence, becomes trans-autophosphorylated itself 18. 
 
 
Inactive monomer  
(EGFR, ErbB3, ErbB4) 
Ligand-bound 
monomer 
Active  
heterodimer 
ErbB2  
monomer 
Figure 1-2: Schematic overview of the structural basis for ErbB receptor dimerization and 
activation 
In the ligand-free state, EGFR, ErbB3, and ErbB4 have a tethered conformation stabilized by 
interaction between the extracellular domains II (CR1) and IV (CR2). Binding of a ligand between the 
extracellular domain I (L1) and III (L2) creates an extended conformation, which exposes the 
dimerization loop of domain II (CR1) allowing for receptor homo- and heterodimerization. Receptor 
dimerization apposes the tyrosine kinase N-lobe of one receptor with the C-lobe of its partner leading 
to C-terminal tyrosine phosphorylation, creating binding sites for adaptors, signaling molecules and 
regulatory proteins. ErbB2 is unique in that it is fixed in the extended conformation ready to interact 
with other ErbB receptors. Figure adapted from Wieduwilt and Moasser, 2008. 
 
Crystal structures of the EGFR extracellular region revealed that in the ErbB family 
dimerization is entirely mediated by the receptor19,20. The bivalent ligand contacts two 
distinct sites within a single receptor molecule (on Domains I and III) promoting 
substantial conformational changes in the extracellular region, which unmask a 
dimerization arm in Domain II14. Before the ligand binds, this arm is completely buried 
by intramolecular interactions with Domain IV that stabilize a ‘tethered’ conformation 
in which both ligand binding and dimerization are autoinhibited19. In 2007, Dawson et 
al. confirmed that the tethered and extended conformations are also adopted in 
solution21. Furthermore, they monitored the transition from a tethered to extended 
configuration in the monomeric extracellular regions of ErbB3. 
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However, the crystal structure of a truncated ErbB2 ectodomain revealed that this 
receptor is locked in the extended conformation22. This is in consistency with the fact 
that no ligand for ErB2 could be identified and facilitates interaction with other 
receptors. 
 
 
Figure 1-3: Structures of human ErbB receptor extracellular regions without bound ligand. 
EGFR, ErbB3 and ErbB4 all adopt the tethered conformation in the absence of ligand, whereas ErbB2 
adopts a tethered conformation. Structures are shown in ribbon representation. The sEGFR structure 
is from Li et al.23, sErbB2 is from Cho et al.24, sErbB3 from Cho and Leahy25, and sErbB4 from 
Bouyain et al.26.Figure from Lemmon 200927. 
 
1.2 ErbB receptor ligands 
ErbB ligands are members of the EGF-like growth factor family. They originate from 
cell membrane anchored proteins28. After proteolytical processing, they are released 
as soluble molecules29,30. Their signaling diversity is achieved by ligand specificity, 
redundancy, processing and variable tissue expression patterns1. Figure 1-4 displays 
ErbB receptors and their ligands.  
EGFR uniquely binds EGF31,32, transforming growth factor-α (TGF-α)33,34, and 
amphiregulin35. ErbB3 binds neuregulin-136 and neuregulin-237-40 and uniquely binds 
Neuroglycan C41. Neuregulin-1 is also known as neu differentiation factor, heregulin, 
and acetylcholine receptor-inducing activity and glial growth factor42,43. ErbB4 is also 
able to bind neuregulin-1 and neuregulin-2 and uniquely binds neuregulin-344, 
neuregulin-445, and tomoregulin46. Both EGFR and ErbB4 bind heparin-binding EGF-
like growth factor (HB-EGF)47, betacellulin48, epiregulin49 and epigen50 (all reviewed 
by Wieduwild and Moasser, 20111). 
Ligand-dependent differences in the patterns of ErbB receptor phosphorylation, as 
first shown for EGFR51, lead to divers downstream signaling characteristics of the 
receptors in distinct dimers, modulated by the respective dimerization partner. 
Moreover, binding of different ligands to ErbB receptors also affects other 
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characteristic receptor properties, like different exposure times on the outer cellular 
membrane. For example, EGFR is internalized faster after EGF binding leading to 
homodimerization, than after activation through NRG binding ErbB451 (reviewed by 
Hynes et al., 20013). 
 
 
Figure 1-4: Binding specificities of the EGF-related peptide growth factors 
Schematic of ErbB receptors and their respective ligands; Hynes et al. proposed a classification of 
ligands that bind ErbB family receptors in four categories. EGF, AR and TGFα bind ErbB1; BTC, HB-
EGF and EPR bind ErbB1 and ErbB4; NRG-1 and NRG-2 bind ErbB3 and ErbB4; NRG-3 and NRG-4 
bind ErbB4. 
 
1.3 ErbB receptor downstream signaling cascades  
Almost all different homo- and heterodimer combinations of ErbB receptors are 
possible12. Which pathways are activated is determined strongly by the identity of the 
bound ligand as well as of the dimerization partner. Different dimers have different 
signaling potencies. Generally, heterodimers are more potent signaling activators 
than homodimers12. Pinkas-Kramarski et al. proposed a specific hierarchy of receptor 
crosstalk: ErbB2/ErbB3 is the most favored heterodimer, followed by ErbB1/ErbB2 
interaction. ErbB1/ErbB1 homodimers are still preferred against ErbB1/ErbB3 
heterodimerization52. ErbB4, the most recently discovered member of the ErbB 
family53,54, is not considered in this study. The hierarchy and selectivity of receptor 
interactions was also confirmed by others55,56. A mathematical model from 
Shankaran et al furthermore indicated that EGFR-HER2 and HER2-HER3 dimers 
both contribute to HER2 activation with the EGFR expression level determining the 
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relative importance of these species, and that the HER2-HER3 dimer is largely 
responsible for HER3 activation57. ErbB2 seems to be the preferred interaction 
partner9, and ErbB3 is its major counterpart55. Noteworthy, the ErbB2/ErbB3 dimer is 
also the most mitogenic receptor pair in the ErbB family58. However, dimerization 
partner selection and thereby signal transduction also depend on expression patterns 
and thereby availability of the different receptors59. Taken together, in healthy cells 
the onset of signaling cascades is controlled by the (tissue-) specific ligand 
availability, followed by receptor expression with a certain bias towards kinetically 
favored dimer pairs. 
The key event for the activation of ErbB receptors is the binding of a growth factor to 
their extracellular domain, inducing a conformational change in this domain and 
thereby allowing receptor dimerization and autophosphorylation of key tyrosine 
residues within the carboxyterminal tail of the receptors14. This provides specific 
docking sites for cytoplasmic proteins containing Src homology 2 (Sh2) and 
phosphotyrosine-binding (PTB) domains (reviewed in Yarden & Sliwkowski, 200112). 
These proteins bind to the specific phosphotyrosine residues and initiate intracellular 
signaling via several pathways60. The enzymatic activity of the tyrosine kinase in the 
intracellular domain of the receptor is also able to phosphorylate tyrosine residues on 
different intracellular adaptor proteins61. 
Most of the intracellular second messengers generated when they are activated are 
shared by all ErbB receptors42. On the other hand, different ErbB dimers recruit or 
activate also different sets of signaling molecules62. For example, the p85 subunit of 
PI3-kinase associates particularly with ErbB363. The two most important pathways 
induced by ErbB receptors, the MAPK and PI3K/Akt pathways, are described in more 
detail in the following. A third important ErbB receptor downstream signaling pathway 
is the phospholipase C (PLCγ) pathway5. 
1.3.1 The MAPK pathway 
All ErbB family members couple via Shc and/or Grb2 to the Mitogen activated protein 
(MAP) kinase pathway42. The first step of this cascade occurs in close proximity to 
the growth factor receptors and involves the activation of a small GTP binding protein 
(Ras) via the adapter molecule (Grb2) and a guanine nucleotide exchange factor 
(Sos). This is followed by the sequential stimulation of several cytoplasmic protein 
kinases64. A similar pattern of sequential activation is used by many pathways64. 
However, the pathway leading to activation of extracellular regulated kinase (Erk) 
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isoforms via mitogen-activated, Erk-activating kinase (MEK) is the principle one in 
growth factor signaling64. In this pathway, Grb2 binds to proline-rich stretches in the 
Ras-guanine nucleotide exchange factor Sos via its N-terminal SH3 domain65, 
enabling the activation of the membrane-associated small GTP binding protein Ras66. 
Activated Ras-GTP promotes the activation of Raf67 by its recruitment to the plasma 
membrane68. Raf kinase then phosphorylates and activates MEK1/2, which then 
phosphorylates and activates ERK1/2. After their activation, ERKs in turn are able to 
phosphorylate various downstream substrates64. ERK substrates are numerous and 
found both in the cytoplasm and in the nucleus and include regulatory proteins as 
well as transcription factors. Thereby, ERKs serve as important regulators of 
transcriptional activity64. Finally, they regulate important cellular processes such as 
proliferation, differentiation and cell cycle progression69. 
1.3.2 The PI3K pathway 
The phosphoinositide-3-kinase (PI3-kinase)-Akt-mTOR pathway can be activated by 
receptor tyrosine kinases as well as by G-protein coupled receptors (GPCRs). It is a 
central signal transduction pathway that regulates many critical physiological 
aspects, including cell proliferation, differentiation, apoptosis, cell morphology and 
migration, protein synthesis, and cell metabolism70. 
Class I PI3-kinases consist of a catalytic (p110) and a regulatory subunit (p85). 
Through binding of the regulatory subunit to activated RTKs or adaptors, PI3K is 
recruited to the plasma membrane where it catalyzes the phosphorylation of the 3’ 
position of its preferred in vivo substrate, the membrane lipid phosphatidylinositol-
4,5-bisphosphate (PIP2) to generate the second messenger phosphatidylinositol 
(3,4,5) trisphosphate (PIP3). PIP3 recruits cytosolic proteins with PIP3-binding 
pleckstrin homology (PH) domains and thereby localizes them to the plasma 
membrane. The Serine/Threonine kinase protein kinase B (Akt) appears to be the 
most notable of the recruited proteins and a major effector of PI3K signaling71. The 
phosphoinositide-dependent kinase Pdk1, also recruited by PIP3, phosphorylates 
threonine 308 of Akt70. The mTOR-containing TORC2 complex mediates Akt 
phosphorylation on serine 473 that is required for full Akt activation. Akt then 
phosphorylates several substrates. One of its key downstream targets is the mTOR 
protein kinase complex. mTOR, the mechanistic target of rapamycin, exists in 2 
distinct multiprotein complexes: mTORC1 and mTORC2. Akt phosphorylates 
tuberous sclerosis complex 2 (TSC2) and PRAS40, which leads to increased 
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mTORC1 kinase activity. mTORC1 regulates protein synthesis and cellular 
metabolism via two major substrates: p70 ribosomal protein S6-kinase (p70S6K) and 
eukaryotic initiation factor 4E binding protein 1 (4EBP1). Akt also catalyzes the 
inhibiting phosphorylation of BAD5 which is pro-apoptotic in its unphosphorylated 
state72. 
The extent and duration of the PI3K/Akt/mTOR pathway is primarily regulated by the 
tumor suppressor phosphatase and tensin homolog (PTEN), which catalyzes the 
dephosphorylation of PIP3 back to PI(4,5)P2 (the PI3-kinase pathway is reviewed by 
Lauring et al.70, Brown and Toker73 and by Klempner et al.74).  
 
 
Figure 1-5: ErbB receptor downstream signaling cascades 
Simplified illustration of the two major pathways triggered upon ErbB activation. After ligand binding, 
the extracellular domains of EGFR, ErbB3 or ErbB4 are stabilized in an extended conformation, 
exposing their dimerization interface and favoring dimerization with for example ErbB2. 
Autophosphorylation of tyrosine residues in the carboxyterminal tail then provides docking sites for 
cytoplasmic proteins, leading to the activation of other protein kinases. The key players in the 
described pathways, Erk and Akt, have multiple targets. They control important cellular processes 
such as gene expression, proliferation, angiogenesis, protein synthesis, survival, cell cycle control, 
and apoptosis suppression. 
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1.4 Alterations of ErbB signaling cascades and their 
implication in cancer 
In 2000, Hanahan and Weinberg proposed six essential alterations in cell physiology 
that essentially all cancer cells have in common75. An update by the same authors in 
2011 adjusted the number of typical alterations to ten76. According to these reviews, 
the first “hallmark of cancer” is self-sufficiency in growth signals. It was the first 
capability of cancer cells clearly described by researchers. Controlling such important 
cellular processes like proliferation and cell cycle control, it is not surprising that 
many alterations of growth signaling pathways are found in multiple cancer types. 
The distinct other five capabilities of cancer cells were specified as “insensitivity to 
anti-growth signals”, “tissue invasion and metastasis”, “limited replicative potential”, 
“sustained angiogenesis” and the capability to evade apoptosis. Today, it is clear that 
ErbB signaling can be involved in most of these hallmarks. 
ErbB members have a pivotal role in mammalian development and tissue 
maintanance1. To protect the cells from uncontrolled mitogenic signaling, the 
pathways are tightly regulated6. Besides control through phosphatases and other 
protein kinases, multiple autoregulatory mechanisms exist6. However, aberrant 
signaling through the ErbB receptors is implicated in many human diseases1. Several 
malignancies are associated with the mutation or increased expression of members 
of the ErbB family including lung, breast, stomach, colorectal, head and neck, and 
pancreatic carcinomas and glioblastoma5. 
Since the discovery of EGF in 196231, huge progress was made unraveling the role 
of growth signaling related oncogenes and their role in cancer evolution, 
homeostasis, progression and treatment resistance. For example, ErbB2 has been 
identified on the basis of its amplification in a human mammary carcinoma in 198577.  
Although induced ErbB homodimer formation is unlikely, unphysiological 
overexpression of ErbB2 leads to the formation of a functional homodimer78. ERBB2 
gene amplification occurs in 20-30% of human breast cancers5 and is associated 
with adverse outcome79. Since breast cancer is the leading cause of female cancer 
deaths worldwide, this is of great importance and dealing with ErbB driven cellular 
aberrations is a big challenge of our time. Overexpression is not only common for 
HER2, but also for EGFR, that is overexpressed in about 40% of glioblastoma 
multiforme (GBM) and 5-10% of NSCLC, based on gene amplification80-82. 
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Besides overexpression of wildtype ErbB receptors, activating mutations are also 
frequently observed. For example, EGFRvIII, where exons 2-7 are deleted, occurs in 
lung, breast, ovarian and prostate cancers and GBM83-85, and activating EGFR 
tyrosine kinase domain mutations have been observed in 10-20% of NSCLCs1. ErbB 
receptor ligands also are frequently expressed in human carcinomas and play an 
important role in the pathogenesis of these diseases61.  
1.5 Rising significance of ErbB3 
ErbB3 possesses only 1/1000th of the autophosphorylation activity of ErbB186. Due to 
this impaired kinase activity ErbB3 is active only after transphosphorylation and 
ErbB3 homodimers are non-functional. Moreover, cancers with driving HER3 
amplifications or mutations have not been found at first87. These facts led to the long 
accepted assumption, that the receptor is not crucial in the context of cancer15,87. 
Therefore, unlike its family members EGFR and HER2, that are well-established 
targets in many different human cancers, the role of HER3 in tumor signaling was 
elucidated relatively recently15. In 2013, Jaiswal et al identified somatic ERBB3 
mutations with transforming potential in ∼11% of colon and gastric cancers88. 
Admittedly, this oncogenic activity was dependent on kinase-active HER2. The group 
also found that anti-ErbB antibodies and small molecule inhibitors could block mutant 
ERBB3-mediated oncogenic signaling and disease progression88.  
Due to the highly interdependent functions of HER proteins, frequently more than one 
of them are implicated in cancer pathogenesis, and HER3 has been identified as an 
obligate partner in HER family oncogenesis. Nowadays, its role as an obligate 
partner is well established in some breast cancers and increasingly suspected in 
several other cancers87. Particularly, it is clear that HER3 plays a critical role in 
HER2-mediated transformation89,90 and its expression correlates with proliferation, 
advanced disease stage and poor prognosis of melanoma91,92, where it probably 
activates EGFR and HER493. There is also evidence, that HER3 is implicated in 
prostate94, colorectal95, lung96 and ovarian97,98 cancer, glioma99 and astrocytoma100. 
Moreover, the analysis of drug resistance in several HER family driven cancers 
highlights a central role for HER3 in mediating treatment failure87. In all, it became 
clear that effective treatment of some cancer types also requires HER3 targeting. 
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1.6 Monoclonal antibodies as therapeutic agents 
ErbB receptors, whose mechanism of action depends on the interaction of their 
extracellular domains with activating ligands and with the ECDs of their dimerization 
partners, are accessible to monoclonal antibodies that can disrupt their function if 
appropriately designed. The first monoclonal antibody (mAb) to enter clinical use for 
cancer treatment purposes was the ErbB2-targeting trastuzumab (Herceptin®), 
developed by Genentech (San Francisco, CA, USA) 101. This humanized version of 
the murine anti-ErbB2 antibody 4D5 supports ADCC and induces downregulation of 
ErbB2102. Clinical trials have demonstrated, that trastuzumab is active in patients with 
high levels of ErbB-2 expression103-105. Pertuzumab (Perjeta®), another humanized 
monoclonal antibody, binds to the dimerization arm of HER2, near the center of 
domain II, which is distinct from the binding site of trastuzumab106. The first clinically 
approved anti-EGFR monoclonal antibody was cetuximab (Erbitux®). This chimeric 
antibody was developed by chimerization with human IgG1 constant region of the 
murine 225 antibody107. Panitumumab (Vectibix®), a fully human monoclonal 
antibody also binding the extracellular domain of EGFR and showing activity against 
colorectal cancer108, is approved for clinical use too.  
Today, many HER3 targeting antibodies are in clinical development. The HER3-
targeting agent that has advanced furthest in clinical development is patritumab (U3-
1287; U3-pharma GmbH, Amgen, Daiichi-Sankyo), a fully human monoclonal 
antibody109. The HER3-specific seribantumab (MM-121) developed by Merrimack 
Pharmaceuticals was generated from a phage-displayed antigen-binding fragment 
(Fab) library. The isolated binder was converted to a full-length human IgG2 format110 
that has been shown to have an anti-proliferative effect in in vivo studies with several 
xenografts111. AVEO Oncology’s humanized IgG1 AV-203 was shown to block 
ligand-binding to the receptor and induce HER3 degradation112. Kolltan 
Pharmaceuticals and Medimmune developed KTN3379 by phage display that locks 
HER3 in an inactive conformation, enabling inhibition of both ligand-dependent and 
independent signaling113.  
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Table 1-1: HER3 targeting monoclonal antibodies. Table adapted from Malm 201615.  
mAb Format Company 
Most 
advanced 
clinical phase 
origin 
affinity to 
human 
HER3 
epitope 
Patritumab 
(U3-1287)109,114 
Human 
IgG1 
U3-Pharma, 
Amgen, 
Daiichi 
Sankyo 
3 XenoMouse
® 
technology 1-3 nM HER3-ECD 
Seribantumab 
(MM-121)110,111 
Human 
IgG2 
Merrimack 
Pharmaceuti
cals, Sanofi 
Avantis 
2 
phage-
displayed 
antigen-
binding 
fragment (Fab) 
library 
0.8 nM domain I  
Elgemtumab 
(LJM716)115 
Human 
IgG1 
Novartis 
Pharmaceuti
cals, Ariad, 
Morphosys 
1/2 
MorphoSys 
phage-
displayed 
HuCal Fab 
library 
32 pM 
interface 
between 
domain II 
and 
IV  
Lumretuzumab 
(RG7116)116,117 
Humani
zed 
IgG1 
Roche, 
Glycart 1 
NMRI mice 
immunized 
with 
recombinant 
HER3 ECD 
0.5 nM domain I  
AV-203112 
Humani
zed 
IgG1 
AVEO 
Oncology, 
Biogen 
1   unknown 
KTN3379113,118 Human IgG1 
Koltan 
Pharmaceuti
cals, 
Medimmune 
1 
phage-library 
screen, 
followed by 
affinity 
maturation 
166 pM 
(monova-
lent) 
border 
between 
domain 2 
and 3 
GSK2849330 
Human-
ized 
IgG1 
Glaxo group 1   domain III 
TK-A3, TK-
A4119,120 
Human-
ized IgG 
Takis Preclinical  7.2 nM, 
2.2 nM  
domain II, 
confor-
mational 
EV20 (MP-RM-
1)121,122 
Human-
ized IgG 
MediaPhar-
ma 
Preclinical   unknown 
Millegen 
patent anti-
HER3123 
Human 
IgG 
MilleGen Ab 
Pharma, 
INSERM 
Preclinical    
Sea Lane 
patent anti-
HER3 (SL175 & 
SL176)124 
Surro-
body 
Sea Lane 
Biotech-
nologies 
Preclinical    
Ablynx patent 
anti-HER3 
Nano-
body 
Ablynx, 
Merck 
Serono 
Preclinical    
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In recent years, bispecific antibodies have also become attractive for tumor-targeting 
purposes. The reason emphasizing the use of this strategy is a potentially enhanced 
functionality15. Different bispecific approaches have been generated to facilitate two-
SGP1 Mouse 
IgG 
University of 
Kent 
Preclinical   unknown 
Merck Co 
patent anti-
HER3 
NR Merck & Co Preclinical    
Immunogen 
patent anti-
HER3 
Human-
ized IgG 
Immuno-Gen Preclinical    
Symphogen 
patent anti-
HER3  
Mouse 
IgG 
Sympho-gen 
A/S 
Preclinical    
KHK patent 
anti-HER3 
Mouse 
IgG 
Kyowa 
Hakko Kirin 
Co 
Preclinical    
Trellis patent 
anti-HER3 
NR Trellis 
Bioscience 
Preclinical    
UAB patent 
anti-HER3 
NR UAB 
Research 
Foundation 
Preclinical    
Genentech 
patent anti-
HER3 
NR Genentech Preclinical    
Sorrento 
patent anti-
HER3 
NR Sorrento 
Thera-
peutics 
Preclinical    
University of 
Texas patent 
anti- 
HER3 
NR University of 
Texas 
Preclinical    
Roche patent 
anti-Her3 
NR Roche Preclinical    
Beijing inst. of 
basic med. sci 
anti-HER3 
NR Beijing 
Institute of 
basic 
medical 
sciences 
Preclinical    
Introduction 
26 
in-one receptor targeting for improved therapeutic efficiency125. For many of them, 
one specificity is directed against HER3 in order to avoid the development of 
acquired resistance against single-targeting agents125-127. Another clinically validated 
cancer-targeting strategy of bispecific antibody molecules is the simultaneous binding 
and engagement of an immune effector cell and a tumor cell to induce cytotoxic 
activity128-130. 
1.7 Small molecule inhibitors 
As the tyrosine kinase function of ErbB members is essential for intracellular 
signaling and cell transformation, inhibition of this enzymatic function also provides a 
rational basis for a class of targeted therapies, namely tyrosine kinase inhibitors 
(TKI)1. These compounds competitively bind within the ATP binding region of the 
kinase domain of ErbB receptors. Therefore, the use of TKIs is an important strategy 
for the treatment of cancers involving mutated ErbB members with a constitutively 
activated kinase domain. Well known examples for this class of compounds are the 
EGFR specific tyrosine kinase inhibitor ZD1839, today known as gefitinib (Iressa®), 
which was developed around the last turn of the millennium, Erlotinib (Tarceva®) and 
Lapatinib (Tykerb®), with gefitinib and erlotinib most active against EGFR and 
lapatinib equally active against EGFR and HER2131,132. The TKIs gefitinib and 
erlotinib are highly active in the treatment of NSCLCs enharbouring activating 
mutations in the tyrosine kinase domain of EGFR133 and lapatinib is approved for the 
use in combination with certain chemotherapies for treatment of breast cancers with 
HER2 overexpression134. 
However, the impaired kinase activity of HER3 makes it a rather unsuitable target for 
small molecule inhibitors and appears pointless as therapeutic strategy. Although 
oncogenic HER3 mutations have been found in a subset of colon and gastric 
cancers, these mutant receptors still required the activity of HER2 for cell 
transformation88. 
1.8 Problems and difficulties of targeted therapies 
Besides the high costs of targeted therapies, the main problems faced today with 
targeted therapies are the lack of effectiveness and (intrinsic or acquired) resistance. 
Although agents directed against the ErbB receptors have shown promising clinical 
activity, the overall rate of response in cancer patients is generally low61. In fact, 
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clinical responses have been observed in a small percentage of patients as 
compared with the frequency of expression of the target receptors61. 
Many reasons for resistance mechanisms against ErbB receptor targeting drugs lay 
in the complexity of the ErbB network. Aberrant signaling due to mutations of 
receptors and/or downstream effectors, aberrant receptor localization and trafficking 
or overexpression of ErbB specific ligands can demolish the action of the 
sophisticatedly designed drugs (as reviewed for cetuximab by Brand et al., 2011135). 
Wheeler et al reported an oncogenic shift in cetuximab-resistant cells through 
increased activation of different RTKs like HER2, HER3 and cMET and increased 
heterodimerization136. Cordo Russo et al identified nuclear ErbB2 as the major 
proliferation driver in trastuzumab-resistant breast cancer cells137. Another challenge, 
also effecting targeted cancer therapy, is the heterogeneity of the different tumor 
cells. Epithelial to mesenchymal transition (EMT) may play a role in resistance to 
cetuximab138. Furthermore, some treatment-resistant cancer cells re-activate pro-
angiogenic factors via alternate pathways, for example through increased VEGF 
production139. Prediction of response to targeted therapy is difficult in many cases. 
For example, early clinical studies did not confirm a correlation between EGFR 
expression level by immunohistochemistry (IHC) and clinical response to EGFR 
inhibiting therapy140. However, De Roock et al found that KRAS mutation status 
strongly predicted the effectiveness of cetuximab for irinotecan-refractory metastatic 
colorectal cancer with a significant increase in overall survival in patients with wild-
type KRAS141. 
 
Regarding side effects, small molecule inhibitors and monoclonal antibodies are 
specific agents that mostly target tumor cells thereby minimizing unwanted adverse 
effects, although they also show low side effects on normal cells142. For HER2 
antagonists like trastuzumab, cardiotoxicity can occur as adverse effect, since these 
receptors are expressed in the heart, where they play an important role for 
maintaining physiologic functions5,143. Early safety data of some of HER3 targeting 
antibodies indicate that they are well tolerated, without reported severe adverse 
effects109,117. However, the relatively low expression level of HER3 on tumor cells, 
along with the expression of this receptor in normal tissues such as liver, lung, small 
intestine, stomach and salivary gland, may render it a challenging tumor antigen15. 
Several strategies are pursued to strengthen the efficacy of ErbB targeted therapy. 
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One way to optimize the efficacy of these therapies used in the clinic is to administer 
these agents in combination with conventional chemotherapy61. Furthermore, 
predictive biomarkers are needed to estimate the potential use of a respective drug. 
As coexpression of different ErbB receptors can lead to increased drug resistance144, 
simultaneous blockade of different signal transduction pathways might result in a 
more significant anti-tumor effect as compared with monotherapy only blocking a 
single pathway. Indeed, several reports support this hypothesis61. 
1.9 Aim of the study 
Targeting of ErbB family members is of great potential in anti-tumor therapy. Different 
antibodies vary in multiple aspects. Different isotypes, mutations or other 
modifications in the constant parts may lead to diverse pharmacokinetics and effector 
functions. Importantly, the large differences concerning the variable domains do, 
through specific epitopes and intrinsic capacities such as binding strength and steric 
issues, affect the mode of action of different antibodies. Regarding the numerous 
challenges of cancer treatment today, there is a need of multiple different drugs to 
enrich treatment options. Furthermore, the analysis of different cancer cell targeting 
antibodies, their intrinsic features and the effects mediated by them implies the 
potential of better understanding both, the biology of cancer cells and the targeted 
structures, i.e. receptors, as well as general correlations between specific antibody 
properties and their clinical benefits. 
 
In this study, multiple antibody binding sites were expressed in the scFv format. A 
screen of these proteins was performed to extract the clones with good cell binding 
properties. The chosen clones were used for the construction of potentially 
therapeutically molecules, i.e. fully human IgG1 antibodies. Analysis of these 
molecules eventually evidenced their biochemical and functional properties and 
effects on tumor cells in vitro. Importantly, a xenograft model in SCID mice was 
performed to demonstrate the anti-tumor activity of the novel HER3 targeting 
antibody in vivo. 
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2 Material and Methods 
2.1 Material 
2.1.1 Instruments and devices 
Balances 440-39N, 440-333N and ALJ 120-4  
(Kern, Balingen, Germany) 
Blotter  TransBlot SD, Semidry transfer cell  
(Bio-Rad, Munich, Germany) 
Centrifuges Eppendorf 5415C, 5810R  
(Eppendorf, Hamburg, Germany) 
J2-MC with rotors JA10, JA14, JA20, JA30.5 
(Beckman Coulter, Krefled, Germany) 
Avanti J-30I (Beckman Coulter, Krefeld, Germany) 
Avanti® J-26XP with rotor JLA-8.1000  
(Beckman Coulter, Krefeld, Germany) 
CO2 incubator (eukaryotic cell culture) Varocell 140 (varolab GmbH, Giesen, Germany)  
Electrophoresis systems Ready Agarose Precast Gel System  
(BioRad, Munich, Germany) 
Mini-PROTEAN 3 Electrophoresis Cell System 
(BioRad, Munich, Germany)  
XCell SureLock® Midi-Cell  
(Thermo Fisher, Waltham, USA) 
Film developing machine  Film Processor Curix 60  
(Agfa, Düsseldorf, Germany) 
Flow cytometer(s) MACSQuant® Analyzer 10, MACSQuant® VYB 
(Miltenyi Biotec, Bergisch Gladbach, Germany)  
Cytomics FC 500  
(Beckman Coulter, Krefeld, Germany) 
Fluorescence microscope Axio observer SD  
(Carl Zeiss AG, Oberkochen, Germany) 
Gel documentation Transilluminator, Gel documentation system Felix 
(Biostep, Jahnsdorf, Germany) 
Heat block HBT-1-131  
(HLC BioTech, Bovenden, Germany)  
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HPLC  Waters 2695 Separation Module, Waters 2489 
UV/Visible detector (Waters Cooperation, Milford, 
USA)  
Imager (immunoblots) FUSION SOLO S (Vilber Lourmat Deutschland 
GmbH, Eberhardzell, Germany) 
Incubator (suspension cells) Infors HT Multitron Cell  
(Infors GmbH, Einsbach, Germany) 
Incubator for bacteria Infors HT Multitron  
(Infors AG, Bottmingen, Switzerland) 
Laminar flow cabinet Variolab Mobilien W90  
(Waldner-Laboreinrichtungen, Wangen, Germany) 
Magnetic stirrer MR 3001K 800W  
(Heidolph Instruments, Nürnberg, Germany 
Microplate reader Tecan infinte M200 (Tecan Austria, Grödig, Austria) 
Microscopes Observation/counting: CKX31 and CK2  
(Olympus, Hamburg, Germany); 
PCR cycler RoboCycler 96 (Stratagene, La Jolla, USA) 
Eppendorf Mastercycler  
(Eppendorf, Hamburg, Germany) 
Quartz crystal microbalance Attana Cell A200 with C-fast system  
(Attana AB, Stockholm, Sweden) 
Spectrophotometer NanoDrop Spectrophotmeter ND-1000  
(PEQLAB, Erlangen, Germany) 
Vortexer Sky Line (Elmi Ltd., Riga, Latvia) 
Western blotting system iBlot® 2 Dry Blotting System  
(Thermo Fisher, Waltham, USA) 
Zetasizer ZetaSizer Nano ZS  
(Malvern Instruments, Herrenberg, Germany) 
2.1.2 Consumables and Implements 
Laboraty plastics were purchased from Greiner Bio-One (Frickenhausen, Germany). 
Consumables purchased from different sources are further specified. 
 
Attana sensor chips Low nonspecific binding-carboxyl chips  
(Attana AB, Stockholm, Sweden) 
Bottle top filter CA Low Protein binding, 500 ml, 0.2 µm/0.45 µm 
(Corning Incorporated, Tewksbury, MA, USA) 
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Centrifuge tubes 13 ml, PP (Sarstedt, Nümbrecht, Germany) 
Chromatography columns Poly-Prep® columns (Bio-Rad, Munich, Germany)  
Cell counting chamber Neubauer 0.0025 mm²  
(Marienfeld, Lauda-Königshofen, Germany) 
Dialysis membrane 23 mm (cut-off 12.4 kDa)  
(Sigma-Aldrich, St. Louis, Germany) 
Dialysis membranes High retention seamless cellulose tubing, 23 mm, 
MWCO 12,400 (Sigma-Aldrich, St. Louis, MO, 
USA); ZelluTrans, MWCO 6,000-8,000, 40 mm; 
ZelluTrans, MWCO 3,500, 46 mm (Carl Roth, 
Karlsruhe, Germany) 
ELISA plates Microlon high binding ELISA plate  
(Greiner Bio-One, Frickenhausen, Germany) 
Gradient gels for SDS Page NuPAGE™ Novex™ 4-12 % Bis-Tris Midi Gels 
(Thermo Fisher, Waltham, MA, USA) 
HPLC columns Yarra™ 3 µm SEC-2000, Yarra™ 3 µm SEC-3000 
(Phenomenex, Torrance, CA, USA); Waters 2695 
HPLC (Waters Corporation, Milford, USA) 
IMAC affinity beads Protino Ni-NTA agarose  
(Macherey-Nagel, Düren, Germany) 
Microscopy slides Chamber slidesTM 
Nitrocellulose membrane (for semidry 
blotting of purified proteins) 
BioTrace™ NT Nitrocellulose Transfer Membrane 
(Pall Life Sciences, East Hills, USA) 
Photo films  BioMax® MR film (Kodak, Stuttgart, Germany) 
Protein A beads TOYOPEARL® AF-rProtein A HC-650F  
(Tosoh Bioscience, Stuttgart, Germany) 
Quartz cuvette 12mm square glass cell for 90 sizing (PCS8501) 
(Malvern Instruments, Herrenberg, Germany) 
Reaction tubes 1.5 ml, 2 ml Safe-Lock  
(Eppendorf AG, Hamburg, Germany  
Syringe filter Acrodisc® 13 mm, 0.2 µm, HT Tuffryn® Membrane 
(Pall Corporation, Port Washington, NY, USA)  
Triple flask 500 cm, Nunclon™ Delta Surface  
(Thermo Fisher Scientific, Waltham, MA, USA)  
Ultrafiltration spin columns Vivaspin 500, 30,000 MWCO PES  
(Sartorius, Göttingen, Germany)  
Western blotting membrane stacks iBlot® NC Regular Stacks  
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(Thermo Fisher, Waltham, USA) 
Whatman filter paper  Whatman® chromatography paper 3mm (A. 
Hartenstein Laborbedarf, Würzburg, Germany)  
2.1.3 Chemicals 
Chemicals were purchased from Carl Roth (Karlsruhe, Germany), Merck (Darmstadt, 
Germany), Sigma-Aldrich (St. Louis, MO, USA), and Roche (Basel, Switzerland). 
Chemicals purchased elsewhere are explicitly stated. 
 
Bond-Breaker® TCEP  0.5 M (Thermo Scientific, Rockford, USA) 
Coomassie Brilliant Blue G250  SERVA Electrophoresis, Heidelberg, Germany  
Propidium Iodide  
2.1.4 Cell culture media and supplements 
Ampicillin 100 mg/ml in H2O (Roth, Karlsruhe, Germany) 
Choleratoxin (CTX) Sigma Aldrich, St. Louis, MO, USA 
Collagen PureCol®-S (Advanced Biomatrix, San Diego, CA, USA) 
DMEM + 4,5 g/L D-Glucose, + L-Glutamine (Thermo Fisher, Waltham, 
USA) 
Doxycycline Merck, Darmstadt, Germany 
DPBS (1x) GIBCO® Dulbecco’s phosphate-buffered saline (Thermo Fisher 
Scientific, Waltham, MA, USA)  
Eosin solution 0.4 % (m/v) eosin G, 0.02 % (w/v) NaN3 in sterile 1x PBS, pH 
7.4 
Fetal calf serum HyClone® research grade fetal bovine serum (Thermo Fisher, 
Waltham, USA) 
FBS Premium (PAN Biotech, Aidenbach, Germany  
(PAA Laboratories, Cölbe, Germany) 
Freestyle F17-medium Supplemented with 4mM GlutaMAX-I, 0.1% Kolliphor P188 
Freezing medium for 
eukaryotic cells 
10% (v/v) DMSO in FCS 
IPTG 1 M isopropyl β-D-1-thiogalactopyranoside as 1000 x stock 
LB Amp, Glc agar plates LB-medium, 2.0 % (w/v) agar, after autoclaving adding of 
ampicillin to 100 µg/ml and 1 % (w/v) glucose 
LB-medium 1 % (w/v) peptone, 0.5 % (w/v) yeast extract, 0.5 % (w/v) NaCl 
Liofectamine Lipofectamine™ 2000 (Thermo Fisher, Waltham, USA) 
Matrigel growth factor reduced matrigel (BD, Franklin Lakes, NJ, USA)) 
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Opti-MEM® (Invitrogen, Karlsruhe, Germany) 
Penicillin/streptomycin 10,000 U/ml / 10,000 µg/ml (100x) GIBCO® 
(Thermo Fisher, Waltham, USA) 
Polyethylenimine (PEI) (Polisciences, Inc., Hirschberg an der Bergstrasse, Germany) 
Puromycin (Sigma-Aldrich, St. Louis, MO, USA)  
RPMI 1640 + 2 mM glutamine GIBCO® (Thermo Fisher, Waltham, USA) 
Trypsin/EDTA 0.5 % (w/v) trypsin, 5.3 mM EDTA (10x) 
(Thermo Fisher, Waltham, USA) 
Trypton N1 (Organo Technie, La Courneuve, France) 
TY 1.6 % (w/v) pepton, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl in 
H2O  
ZeocinTM 100 mg/ml in H2O (Thermo Fisher, Waltham, USA) 
2.1.5 Buffers and solutions 
Bradford reagent  (5x) Bio-Rad protein assay (Bio-Rad, Munich, Germany)  
Competent cell solution 1  0.1 M CaCl2 in 1x PBS  
Competent cell solution 2  20 % (v/v) glycerol, 50 mM CaCl2 in 1x PBS  
Coomassie staining solution 0.008 % (w/v) Coomassie Brilliant Blue G-250 (SERVA 
Electrophoresis, Heidelberg, Germany), 35 mM HCl  
DNA loading dye (6 x) 10 mM Tris-Hcl pH 7.6, 0.03 % (w/v) xylene cyanol FF, 
0.03 % (w/v) bromophenol blue, 60 mM EDTA, 60 % (v/v) 
glycerol (Thermo Fisher Scientific, Waltham, MA, USA)  
ELISA blocking buffer/MPBS 2 % (w/v) non-fat dry milk powder in 1x PBS  
ELISA developing substrate 
solution 
100 mM sodium acetate pH 6.0, 0.1 mg/ml TMB, 0.006 % 
(v/v) H2O2  
ELISA stopping solution 1 M H2SO4 
ELISA washing buffer/PBST 0.005 % (v/v) TWEEN 20 in 1x PBS  
IMAC elution buffer 250 mM imidazole in 1x sodium phosphate buffer  
IMAC wash buffer 20 mM imidazole in 1x sodium phosphate 
buffer 
Laemmli sample buffer (5 x) Non-reducing: 10 % (w/v) SDS, 25 % (v/v) glycerin, 0.05 
% (w/v) bromphenol blue in 312.5 mM Tris-Hcl pH 6.8;  
Reducing: non-reducing buffer, 25 % (v/v) β-
mercaptoethanol  
PBA 2 % (v/v) FBS, 0.02 % (w/v) NaN3 in 1x PBS  
Periplasmic preparation buffer 30 mM Tris-Hcl pH 8.0, 20 % (w/v) sucrose, 1 mM EDTA  
Phosphate-buffered saline 80.6 mM Na2HPO4, 14.7 mM KH2PO4, 1.37 M NaCl, 
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(PBS, 10x) 26.7 mM Kcl; used as 1x PBS pH 7.5  
Protease inhibitors complete protease inhibitors (Roche, Basel, Switzerland) 
Protein A elution buffer 100 mM glycine-Hcl pH 3.0  
Protein A neutralization buffer 1 M Tris-Hcl, pH 8.0  
RIPA buffer 50 mM Tris pH 7.5, 150 mM NaCl, 10 mM NaF, 20 mM β-
Glycerophosphate, 1 mM EDTA, 1 % NP-40, 1 mM 
Na3VO4, 0.5 mM PMSF, 0.25 % DOC, 0.1 % SDS in 
H2O 
SDS running buffer (10 x) 1.92 M glycine, 0.25 M Tris, 1 % SDS, pH 6.8; 
NuPAGE® MES Running Buffer (Thermo Fisher, 
Waltham, MA, USA); NuPAGE® Antioxidant (Thermo 
Fisher, Waltham, MA, USA) 
Sodium phosphate buffer (5x, 
250 mM) 
210 mM Na2HPO4, 40 mM NaH2PO4, 1.25 M NaCl, pH 
7.5  
TAE (50x) 2 M Tris, 1 M glacial acetic acid, 50 mM EDTA, pH 8.0  
Western Blot – blotting buffer  20 % (v/v) methanol, 192 mM glycine, 25 mM Tris, pH 8.3  
Western blot washing solution 0.05 % (v/v) Tween 20 in 1x PBS  
Blocking reagent Roche, Basel, Switzerland 
Protein A wash buffer 100 mM Tris-Hcl pH 7.5  
Western blot solution A 0.1 M Tris, 0.25 mg/ml luminol, pH 8.6  
Western blot solution B 0.11 % (w/v) p-coumaric acid in DMSO  
2.1.6 Detection antibodies  
Table 2-1: Antibodies used for ELISA, FACS analysis, immunoblotting and microscopy. 
Antibody Source  Application 
Anti-Akt (pan) Mouse; #2920, Cell Signaling  
(Danvers, MA, USA) 
WB (1:2000) 
Anti-EGFR Rabbit polyclonal IgG (Santa Cruz 
Biotechnology, Santa Cruz, USA, #sc-03-G) 
WB (1:500) 
Anti-Erk1/2 Mouse; #9107, Cell Signaling  
(Danvers, MA, USA)  
WB (1:2000) 
Anti-HER2 Mouse mAb  
(Thermo Fisher, Waltham, USA) 
WB (1:1000) 
Anti-HER3 #MA5-12675; Thermo Fischer Scientific 
(Waltham, MA, USA) 
WB (1:1000) 
Anti-His6-FITC  Mouse monoclonal IgG1  
(dianova, Hamburg, Germany) 
FACS (1:200) 
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Anti-His6-PE  Mouse IgG1; Miltenyi Biotec;  FACS (1:200) 
Anti-human EGFR AY13; BioLegend  
(San Diego, CA, USA) 
FACS (expression 
analysis; 1:10) 
Anti-human erbB2/HER-2 Clone 24D2; BioLegend  
(San Diego, CA, USA) 
FACS (expression 
analysis; 1:10) 
Anti-human erbB3/HER-3 Clone1B4C3; BioLegend  
(San Diego, CA, USA) 
FACS (expression 
analysis, 1:10) 
Anti-human IgG (Fab-
specific)-HRP 
Sigma-Aldrich (St. Louis, MO, USA) WB (1:20000) 
Anti-human IgG (Fc 
specific)-HRP 
Polyclonal; Sigma-Aldrich  
(St. Louis, MO, USA) 
ELISA/WB 
(1:5000) 
Anti-human IgG (whole 
molecule)-HRP 
Polyclonal; Sigma-Aldrich  
(St. Louis, MO, USA) 
ELISA/WB 
(1:20000) 
Anti-human IgG (γ-chain 
specific)-R-PE 
Sigma-Aldrich (St. Louis, MO, USA) FACS (1:500) 
Anti-mouse IgG (Fc 
specific)-HRP 
Polyclonal; Sigma-Aldrich  
(St. Louis, MO, USA) 
WB (1:4000) 
Anti-phospho-Akt 
(Thr308) 
Mouse; Cell Signaling (Danvers, MA, USA) WB (1:1000) 
Anti-phospho-Akt 
(Thr308) XP® 
Rabbit; #13038, Cell Signaling  
(Danvers, MA, USA) 
WB (1:1000) 
Anti-phospho-EGFR  
(Tyr 1068) XP® 
Rabbit mAb #3777, Cell Signaling 
Technology® (Danvers, MA, USA) 
WB (1:1000) 
Anti-phospho-Erk1/2 
(Thr202/Tyr204) 
Rabbit polyclonal; #9101. Cell Signaling 
(Danvers, MA, USA) 
WB (1:1000) 
Anti-phospho-HER2 
(Tyr1221/1222) 
Rabbit mAb, #2243, Cell Signaling 
Technology® (Danvers, MA, USA)  
WB (1:1000) 
Anti-phospho-HER3 
(Tyr1289) 
Rabbit; #4791, Cell Signaling  
(Danvers, MA, USA) 
WB (1:1000) 
Anti-rabbit-IgG-
Peroxidase 
Goat polyclonal; Sigma-Aldrich  
(St. Louis, MO, USA) 
WB (1:5000) 
Anti-αTubulin Mouse; #T6793, Sigma-Aldrich  
(St. Louis, MO, USA) 
WB (1:2000) 
His-probe (H3) HRP Mouse monoclonal; Santa Cruz 
Biotechnology (Dallas, TX, USA) 
ELISA/WB 
(1:1000) 
Purified Mouse IgG1 κ 
Isotype Control 
554121. BD Biosciences FACS (expression 
analysis, 1:10) 
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Purified Mouse IgG2a, κ 
Isotype Control 
Clone MOPC-173, Cat. # 400202 
BioLegend (San Diego, CA, USA) 
FACS (expression 
analysis, 1:10) 
Purified Mouse IgG2b κ 
Isotype Control 
555740. BD Biosciences FACS (expression 
analysis, 1:10) 
2.1.7 Proteins and therapeutic antobodies 
Annexin V-GFP kindly provided by Faban Richter, Institue of Cell Biology and 
Immunology, University of Stuttgart 
Atrosab Baliopharm, Basel, Switzerland 
Cetuximab Erbitux® Merck, Darmstadt, Germany 
HER2-Fc extracellular domain (aa 23-652) fused to the human Fcγ1 chain;  
kindly provided by Meike Hutt, Institue of Cell Biology and 
Immunology, University of Stuttgart 
HER3-Fc extracellular domain (aa 20-643) fused to the human Fcγ1 chain;  
kindly provided by Sina Fellermeier, Institue of Cell Biology and 
Immunology, University of Stuttgart 
HER3-His extracellular domain (aa 23-652) ; kindly provided by Jonas Honer 
(Institue of Cell Biology and Immunology, University of Stuttgart) 
or reproduced for this thesis 
Heregulin PeproTech (Hamburg, Germany) 
recombinant heregulin-β; Sigma-Aldrich (St. Louis, MO, USA) 
His-tagged heregulin Ser20-Lys241 NRG1, c-Terminal 6-His-tag; R&D systems 
(Minneapolis, MN, USA) 
Mouse HER2 Mouse HER2 (P70424) extracellular domain (Met 1-Thr 653) 
fused with the Fc region of human IgG1 at the C-terminus. 
Sino Biological Inc.   
Mouse HER3 R&D systems (Minneapolis, MN, USA) 
Rituximab (MABTHERA) Roche, Basel, Switzerland 
Trastuzumab Herceptin® Roche, Basel, Switzerland 
2.1.8 Enzymes 
Lysozyme Muramidase from hen egg white; Roche Diagnostics, 
Mannheim, Germany 
Pfu DNA Polymerase Thermo Fischer, Waltham, MA, USA 
Restriction enzymes Thermo Fischer, Waltham, MA, USA  
(AgeI, ApaI, BamHI, EcoRI, HindIII, MscI, NcoI, NotI, SfiI) 
T4 DNA Ligase Thermo Fischer, Waltham, MA, USA 
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2.1.9 Markers 
GeneRulerTM DNA Ladder mix Fermentas, St. Leon-Rot, Germany  
PageRulerTM Fermentas, St. Leon-Rot, Germany  
2.1.10 Kits 
Alanine Transaminase Activity Assay kit abcam, Cambridge, UK  
Amine coupling kit (EDC + sNHS) Attana AB, Stockholm, Sweden 
Cell Counting Kit-8 (CCK-8)  Sigma Aldrich, St. Louis, USA 
Cy5 Ab Labeling Kit GE Healthcare UK eLimited, Buckinghamshire, 
UK 
DC™ Protein Assay  BioRad, Munich, Germany 
DreamTaq™ Green PCR Master Mix  Fermentas, St. Leon-Rot, USA 
NucleoBond Xtra Maxi Machery-Nagal, Düren, Germany 
NucleoBond® Xtra Midi Machery-Nagal, Düren, Germany 
NucleoSpin® Gel & PCR Clean-up Machery-Nagal, Düren, Germany 
NucleoSpin® Plasmid Machery-Nagal, Düren, Germany 
QIFIKIT® Dako; purchased from Biozol (Eching, 
Germany) 
REDTaq ReadyMix PCR Reaction Mix  Sigma Aldrich, St. Louis, USA 
2.1.11 Bacteria 
Escherichia coli TG1  Genotype: supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5 (rK- mK-) 
[F’ traD36 proAB lacIqZΔM15] (Stratagene, La Jolla, CA, USA)  
2.1.12 Eukaryotic cell lines 
All eukaryotic cell lines were incubated in a humidified atmosphere of 5 percent CO2 
at 37 °C. A549 cells were obtained from CLS Cell Lines Services (Eppelheim, 
Germany). FaDu cells were obtained from DSMZ German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany). BT-474 and SKBR-3 
cells were originally obtained from Nancy Hynes, Friedrich Miescher Institute, Basel, 
Switzerland. MCF-7 cells were originally obtained from Cornelius Knabbe, Institute of 
Clinical Pharmacology, Stuttgart, Germany. Inducible Caco-2 K-RasG12V cells were 
originally obtained from Tilman Brummer, Institute for Molecular Medicine and Cell 
Research, Freiburg, Germany. NCI-N87 cells were kindly provided by TRON, Mainz, 
Germany.  
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Table 2-2: Eukaryotic cell lines used in this study. 
Cell line Origin Culture medium 
A431 human epidermoid carcinoma RPMI 1640 + 10% FCS 
A549 human lung carcinoma (NSCLC) RPMI 1640 + 10% FCS 
BT-474 human ductal carcinoma, breast RPMI 1640 + 10% FCS 
Caco-2 human colorectal adenocarcinoma RPMI 1640 + 10% FCS 
Caco2 Tet-
on K-Ras 
human colorectal adenocarcinoma, 
inducible K-RasG12V 
DMEM + 10% FCS 
Colo205 human colorectal adenocarcinoma RPMI 1640 + 10% FCS 
FaDu human squamous cell carcinoma 
(head and neck cancer; pharynx)  
DMEM + 10% FCS 
HCT-116 human colorectal carcinoma RPMI 1640 + 10% FCS 
HEK293-6E human embryonic kidney, suspension 
optimized 
F17 Freestyle medium 
supplemented with L-Glutamine, 
Kolliphor P-188 and 25 µg/ml G418 
HEK293T human embryonic kidney RPMI 1640 + 5% FCS 
MCF-7 human adenocarcinoma, breast RPMI 1640 + 10% FCS 
NCI-N87 human gastric carcinoma RPMI 1640 + 10% FCS 
SKBR-3 human adenocarcinoma, breast DMEM + 10% FCS 
SKOV-3 human adenocarcinoma, ovary DMEM + 10% FCS 
2.1.13 Mice 
SCID® Beige CB17.Cg-PrkdcscidLystbg/Crl (Charles River, Wilmington, MA, USA)  
2.1.14 Plasmids 
Table 2-3: Plasmids used in this study. 
Plasmid Cloned by 
pAB1-scFv 2-31 Lisa Schmitt 
pAB1-scFv 2-32 Lisa Schmitt 
pAB1-scFv 2-33 Lisa Schmitt 
pAB1-scFv 2-34 Lisa Schmitt 
pAB1-scFv 2-35 Lisa Schmitt 
pAB1-scFv 2-36 Lisa Schmitt 
pAB1-scFv 2-37 Lisa Schmitt 
pAB1-scFv 3-38 Lisa Schmitt 
pAB1-scFv 3-39 Lisa Schmitt 
pAB1-scFv 3-40 Lisa Schmitt 
pAB1-scFv 3-41 Lisa Schmitt 
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pAB1-scFv 3-42 Lisa Schmitt 
pAB1-scFv 3-43 Lisa Schmitt 
pAB1-scFv 3-44 Lisa Schmitt 
pAB1-scFv 3-45 Lisa Schmitt 
pAB1-scFv3M6 Meike Hutt, 2012, Institute of Cell Biology and Immunology 
pAB1-scFv4D5 Sina Fellermeier, 2011, Institute of Cell Biology and 
Immunology 
pAB1-scFvGal12 Institute of Cell Biology and Immunology 
pAB1-scFvhu225 Anja Nusser, 2008, Institute of Cell Biology and Immunology 
pEE14.4-IgG 2-35 SI Lisa Schmitt 
pEE14.4-IgG 3-43 SI Lisa Schmitt 
pEE14.4-IgG 3M6 SI Lisa Schmitt 
pSecTagA-HER2-Fc Sina Ferrlermeier, 2011, Institute of Cell Biology and 
Immunology 
pSecTagA-HER3-Fc Sina Fellermeier, 2011, Institute of Cell Biology and 
Immunology 
pSecTagA-HER3DII-IV-Fc Lisa Schmitt 
pSecTagA-HER3DIII-IV-Fc Lisa Schmitt 
pSecTagA-HER3DIV-Fc Lisa Schmitt 
pSecTagA-His-HER3-ECD Jonas Honer, 2016, Institute of Cell Biology and Immunology 
pSecTagAge-scFv 2-31-Fc Lisa Schmitt 
pSEcTagAge-scFv 2-33-Fc Lisa Schmitt 
pSecTagAge-scFv 2-35-Fc Lisa Schmitt 
pSecTagAge-scFv 3-43-Fc Lisa Schmitt 
2.1.15 Primers/Oligonucleotides 
Table 2-4: Primer for cloning of scFv-Fc fusion proteins: 
# Name Sequence 
1076 AgeI-Her2-31/32/33-back aaa accggt caa gtc cag ctg gtg cag tct 
1077 AgeI-Her2-34/35-back aaa accggt caa atg cag ctg gta cag 
1078 AgeI-Her3-39/43/44-back aaa accggt cag gta cag ctg cag cag 
1079 NotI-Her2-31-33-Her3-39/43/44-fwd aaa gcggccgc acc tag gac ggt cag ctt 
1080 NotI-Her2-34/35-fwd aaa gcggccgc acc tag gac ggc cag ttt 
 
Table 2-5: Primer for cloning of HER3-Fc fusion proteins: 
# Name Sequence 
1226 tHer3DII-III-IV-back aaa g gcc cag ccg gcc tcc gag gtg ggc aac tct cag acc atc 
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tgt gct cct cag tgt aat gg 
1227 tHer3DIII-IV-back aaa g gcc cag ccg gcc tcc gag gtg ggc aac tct cag aaa gcc 
tgt gag gga aca ggc 
1228 tHer3DIV-back aaa g gcc cag ccg gcc tcc gag gtg ggc aac tct cag cac tgc 
aac ttt ctg aat ggg gag 
1229 tHer3-fwd aaa cgg tgg gca tgt gtg agt ttt gtc 
 
Table 2-6: Primer for Cloning of IgG1 molecules 
# Name Sequence 
1240 MscIVL43 fwd aaatggccaaa cag cac tgt cag ctt ggt gcc tcc gcc aaa 
1241 AgeIVL43IgG back aaa acc ggt caa gtg cag ctg cag cag   
1256 AgeIVL43backneu aaa accggt caa gcc gga ctg 
 MscIVL43forneu aaa tggcca ca cag cac tgt cag ctt ggt 
1291 IgGVL43MscIfor aaa ctggccaagcactgtcagcttggtgcc 
1298 MscIIgGVL3M6for aaa ctggcca agc acg gtc act ttg gt 
1299 AgeIIgGVL3M6back aaa accggt cag tct gcc ctg aca cag cct gcc agc gtg tcc ggc 
agc cca ggg cag agc atc aca atc agc 
1300 AgeIVIgGH3M6back aaa acc ggt gaa gtg cag ctg 
1301 ApaIIgGVH3M6for gct ggg gcc ctt ggt gct agc act cga gac tgt gac cag 
1258 AgeIVH43back aaa gag ctc acc ggt caa gtg 
1259 ApaIVH43CH1for aaa ggggcccttggtggaggc aga gga cac tgt gac cat 
 
Table 2-7: Primer for screening and sequencing 
# Name Sequence 
61 LMB4  (pAB1 reverse) gcaaggcgattaagttgg 
82 Lonza-F gcc acc aga cat aat agc 
88 LMB3 (pAB1 forward) cag gaa aca gct atg acc 
89 pET-Seq1/T7-back taatacgactcactataggg 
91 pSec-Seq2  tagaaggcacagtcgagg 
2.1.16 Vectors 
pAB1 Vector for prokaryotic protein expression and secretion into the 
periplasm of E.coli (R. Kontermann) 
pAB1-huCλ Prokaryotic expression vector comprising the constant region of human 
IgG lambda light antibody chain 
pEE14.4 Glutamine synthetase encoding eukaryotic expression vector (Lonza 
Biologics, Berkshire, UK) 
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pEE6.4 Lonza Biologics, Berkshire, UK 
pEE6.4-HCg1e*-
Acc 
pEE6.4 containing human IgG1γ1 heavy chain constant region 
containing point mutations encumbering ADCC and CDC 
pHAL14 phagemid vector derived from pHAL1 (University of Braunschweig145,146) 
pSecTagA Vector for eukaryotic protein expression and secretion (Thermo Fisher 
Scientific, Waltham, MA, USA)  
pSecTagA-Fc Eucaryotic expression vector originated from pSecTagA; comprising 
human IgG Fc-part heavy chain constant regions (hinge, CH2 and CH3 
of human Fcγ1 chain)  
pSecTagA-His Modification of pSecTagA lacking the myc epitope (Gerhard Trunk, 
2005, Institute of Cell Biology and Immunology)  
pSecTagAge-
Fc(lägerer linker) 
Modification of pSecTagA-Fc with additional AgeI restriction site and 
longer linker before the hinge region 
2.1.17 Software and online tools 
Attana evaluation software 3.3.4 Attana AB (Stockholm, Sweden) 
C-Fast Software Attana AB (Stockholm, Sweden) 
Citations EndNote basic (Thomson Reuters, Stuttgart, Germany) 
Data evaluation GraphPad Prism® 5.00 for windows  
(GraphPad Software, La Jolla, CA, USA); 
Microsoft® Excel® für Mac 2011 Version 14.6.9 
(Microsoft, Redmont, WA, USA)  
Flow cytometry software MACSQuantify 2.6  
(Milteny Biotec, Bergisch Gladbach, Germany); 
FlowJo 7.6.5 (Tree Star Inc., Ashland, OR, USA) 
Microscopy software ZEN and ZEN lite  
(Carl Zeiss Microscopy GmbH, Jena, Germany) 
Molecular biology software Serial Cloner 2.6.1 
(http://serialbasics.free.fr/Serial_Cloner.html) 
Protein database UniProt (http://www.uniprot.org) 
Protein parameter determination ExPASy ProtParam (http://web.expasy.org/protparam/) 
Sequence alignment BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) 
TraceDrawer 1.6 Attana AB (Stockholm, Sweden) 
Western blot quantification FUSION SOLO S software (Vilber Lourmat Deutschland 
GmbH, Erberhardzell, Germany) 
Writing Microsoft® Word für Mac 2011 Version 14.6.9 
(Microsoft, Redmont, WA, USA) 
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2.2 Methods 
2.2.1 Molecular biological Methods 
2.2.1.1 Subcloning of scFv proteins 
All scFv fragments consisted of the variable domains of an antibody’s heavy (VH) and 
light chain (VL) joined by a flexible linker (GSASAPKLEEGEFSEARV) and comprised 
a C-terminal hexahistidyl (His6)-tag. For periplasmatic expression, all scFv clones 
were subcloned from pHAL14 into pAB1. All plasmids and pAB1 vector were 
digested with NcoI and NotI. Digested scFv sequences were analyzed by 
electrophoresis, excised, purified and religated into dephosphorylated pAB1 vector. 
2.2.1.2 Cloning of scFv-Fc fusion proteins 
The scFv sequences were amplified from the pAB1 plasmids with the respective 
primers (Table 2-4), to introduce an additional AgeI restriction site at the N-terminal 
site. The resulting PCR products were analyzed by electrophoresis, purified and 
digested with AgeI and NotI. Then, they were ligated in the parallel digested vector 
pSecTagAge-Fc (longer linker). 
2.2.1.3 Cloning of Fc-fused HER3-ECD fractions 
HER3-ECD fractions were amplified by polymerase chain reaction from pSecTagA-
HER3-Fc, inserting a SfiI restriction site at the N-terminal site. HER3-ECD fraction 
sequences were purified and subcloned into pSecTagA-Fc using SfiI and NotI 
restriction sites. 
2.2.1.4 Cloning strategy of IgG molecules 
All variable light chain sequences were lambda light chain sequences. For IgG 3-43 
and IgG 2-35, variable sequences were codon optimized and synthesized from 
GeneArt (Regensburg, Germany). Variable light chain sequences were cloned via 
AgeI and MscI restriction sites into pAB1-huCλ. The resulting signal peptide - VL - 
CLλ -sequences were subcloned via HindIII and EcoRI restriction sites into pEE14.4.  
VH sequences were subcloned into pEE6.4-huEmp1CH1-CH3 (IgG1e3*; pEE6.4-
HCg1e*-Acc, human allotype G1m1,17) using AgeI and ApaI restriction sites. The 
nucleic acid sequence of human IgG1γ1 heavy chain containing S239D and I332E 
amino acid exchange inducing mutations was also ordered as ApaI-EcoRI-fragment 
from GeneArt and subcloned using ApaI and EcoRI restriction sites into VH 
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containing pEE6.4 vector. Finally, heavy and light chains were combined via NotI and 
BamHI restriction sites into pEE14.4. 
2.2.1.5 Handling of E. coli strains 
E. coli strains were cultured at 37 °C, either in Luria-Bertani (LB) medium with strong 
agitation or on agar plates (LB medium containing 3 % Agar). Resistant bacteria 
were selected with media containing 100 mg/l Ampicillin or Kanamycin, according to 
the respective resistance gene. 
2.2.1.6 Chemical competent E. coli cells 
Calciumchlorid-Methode (Sambrook & Russell, 2001) or (Inoue et al., 1990) 
A fresh overnight culture of E. coli TG1 was used to inoculate 300 ml of LB medium 
(dilution 1:100). Cells were grown at 37 °C (shaking at 170 rpm) until an OD600 of 0.5 
to 0.6 was reached and then chilled on ice for 15 minutes in pre-cooled 50 ml 
centrifugation tubes. After centrifugation (4000x g, 5 minutes, 4 °C), the supernatant 
was discarded and the cell pellet was carefully resuspended in 50 ml ice-cold 0.1 M 
CaCl2 in 1x PBS and incubated for 30 minutes on ice. Cells were centrifuged again 
(4000x g, 5 minutes, 4 °C) and cell pellet was resuspended in 10 ml ice-cold 20 % 
(v/v) glycerol/50mM CaCl2 in 1x PBS. Finally, the competent cells were quick-frozen 
in liquid nitrogen and stored in 300 µl aliquots at -80 °C. 
2.2.1.7 Polymerase chain reaction 
Polymerase chain reaction (PCR) with pfu-DNA-polymerase was used to amplify 
desired DNA fragments from vector templates for further cloning steps. A typical PCR 
mixture contained 50 µl: 
 
10x pfu-polymerase buffer + MgSO4 5 µl 
Forward primer (10 pmol/µl)  1 µl 
Reverse primer (10 pmol/µl)  1 µl 
dNTPs (5 mM each nucleotide)  2 µl 
pfu-DNA-polymerase (2.5 U/µl)  1 µl 
dH2O      40 µl 
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2.2.1.8 DNA electrophoresis and gel extraction 
Horizontal agarose gel electrophoresis was used to analyze and purify PCR-
amplified or digested DNA fragments. Depending on the size of the fragments, 0,8 - 
2 % (w/v) agarose was dissolved in 1x TAE buffer by boiling in a microwave oven. 
Subsequently, ethidium bromide was added to a final concentration of 1 µg/ml. The 
solution was poured in specialized trays and polymerized by cooling down to room 
temperature. DNA was mixed 5x DNA loading buffer and applied to the precast gel. 
Electrophoresis was conducted in 1x TAE buffer at a constant voltage of 80 -100 V 
for 30-120 minutes. DNA was visualized using ultraviolet light. The relevant bands 
were excised and purified with a NucleoSpin® Gel and PCR Clean-up kit according 
to the manufacturer’s protocol. The DNA was eluted in 30 µl ddH20. 
2.2.1.9 Restriction digestion 
Restriction digestion was performed in a total volume of 50 µl containing 10 µg vector 
DNA or the complete extracted PCR products from an agarose gel. The digestions 
were performed consecutively for at least one hour per digestion reaction, with a 
buffer exchange performed with the NucleoSpin Gel and PCR Clean-up kit in 
between. The vector DNA was dephosphorylated using 1 U fast alkaline 
phosphatase after the last digestion step for 1 hour at 37 °C. Either all fragments or 
only the digested insert DNA were analyzed via agarose gel electrophoresis. 
2.2.1.10 Ligation 
Insert DNA and 50 - 100 ng linearized dephosphorylated vectors were mixed at a 
molar ratio of 3:1 or 5:1 and incubated with 1 µl T4 DNA ligase according to the 
manufacturer’s protocol in a total volume of 20 µl 1x ligase buffer in sterile water. If 
DNA concentrations were not determined, 15 µl of insert DNA were mixed with 2 µl 
vector DNA, 2 µl Ligase buffer and 1 µl T4 DNA Lidase. For control purposes, a 
sample without insert DNA was also prepared. Incubation was performed for at least 
one hour at room temperature. 10 µl of the reaction mixtures were used for the 
transformation of chemical competent E. coli cells.  
2.2.1.11 Heat shock transformation of E.coli cells 
Chemically competent E.coli TG1 cells were thawed on ice and mixed with 10 µl of 
the ligation preparation. The mixture was incubated on ice for 10 minutes, mixed by 
gentle flipping and incubated for one minute at 42 °C. After another 10 minutes 
incubation on ice, 1 ml of LB medium was added and the cells were incubated for at 
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least 30 minutes at 37 °C under agitation. Afterwards, the cells were harvested by 
centrifugation (1 min, 16,000g) and plated on agar plates containing glucose and 
ampicillin as selection marker and incubated overnight at 37 °C.  
2.2.1.12 Plasmid DNA isolation and sequence analysis 
One single clone was inoculated into a 5 ml/100 ml/500 ml LB medium 
(Mini/Midi/Maxi-preparation) containing 1 % (w/v) glucose and ampicillin, and shaken 
over night at 37 °C. Cells were harvested the next day and DNA was purified 
according to manufacturer’s protocol with the NucleoSpin Plasmid kit for Mini-
preparation or the NuceloBond Xtra Midi or Maxi kit for Midi or Maxi-preparation. The 
DNA was sequenced by GATC Biotech AG (Konstanz, Germany) using the 
corresponding primers from Table 2-7. 
2.2.2 Cell culture and transfection 
All eukaryotic cell lines were cultivated at 37 °C in a humidified 5 percent CO2 
atmosphere in cell culture medium. Cell lines were passaged once, twice or thrice 
weekly, dependent on the respective confluence and growth rates, by detaching 
adherent cells with Trypsin/EDTA, centrifugation (1500 rpm, 3-5 minutes) and 
splitting 1:5 - 1:20. For long-term storage, harvested cells were resuspended in FCS 
containing 10 % (v/v) DMSO and slowly frozen in isopropanol filled cryoboxes to -
80 °C. For thawing, cells were incubated at 37 °C, centrifuged (1500 rpm, 5 min) to 
remove the residual DMSO and resuspended in the corresponding medium. 
 
For selection of HEK293 cells to express recombinant protein, pSecTagA plasmids 
were transfected by lipofection. 106 cells were seeded in a 6-well tissue culture plate 
overnight in 2 ml culture medium. The next day, 330 µl of serum free Opti-MEM 
medium were incubated with 7 µl Lipofectamine 2000 for 5 minutes and subsequently 
mixed with 3 µg plasmid DNA. The culture medium was withdrawn from the cells and 
replaced by 1.5 ml Opti-MEM. After 20 min incubation, the lipofectamine-DNA 
solution was carefully applied to the cells and incubated over night at 37 °C. 
Supernatant was then removed and cells were detached and transferred to 10 cm 
tissue culture plates with culture medium. For selection, zeocin was added after 
4 hours to a final concentration of 300 µg/ml. Upon successful selection, zeocin 
concentration was reduced to 50 µg/ml. 
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2.2.3 Expression and purification of recombinant proteins 
2.2.3.1 Periplasmic protein expression in E. coli TG1 
All scFv analyzed in this study were expressed in E. coli TG1 cells. 1 l of TY medium 
containing ampicillin and 0.1 percent (w/v) glucose were inoculated 1:100 from an 
overnight culture of pAB1 transformed E. coli TG1 and shook at 37 °C until reaching 
an OD600 of 0.8. The protein expression was induced by the addition of IPTG, 
followed by 3 hours of shaking at room temperature. Cells were harvested (6000 g, 
10 minutes, 4 °C) and the cell pellet was resuspended in 100 ml resuspension buffer. 
From now, all steps were performed on ice and with chilled liquids and centrifuges. 
Cell wall lysis was accomplished by addition of 10 mg lysozyme and 30 min 
incubation, followed by the addition of MgSO4 to a final concentration of 10 mM to 
stabilize the spheroblasts. After centrifugation (10,000 g, 30 minutes), the 
supernatant was collected and dialyzed over night against 5 l PBS. The dialyzed 
solution was subjected to purification via IMAC. 
2.2.3.2 Protein expression in stably transfected HEK293T cells 
All Fc fusion proteins used in this study were expressed in stably transfected 
HEK293T cells. After selection, stably transfected cells were expanded to triple flasks 
(Thermo Fisher Scientific, Darmstadt, Germany) in their selection medium. HEK293T 
cells were incubated in RPMI 1640 with 5 percent FCS and 50 µg/ml zeocin. Upon 
reaching 80 percent confluence, the medium was changed to serum free Opti-MEM, 
which was collected every other day for up to two weeks. All further steps were 
carried out at 4 °C. Proteins from cell free supernatant (centrifugation at 500 g for 
5 minutes) were precipitated by addition of 390 g/l ammonium sulfate ((NH4)2SO4) 
addition and stirring for one hour. Consequently, the protein was harvested by 
centrifugation (11,250 g, 30 min) and the resulting pellet was resuspended in cold 
PBS. Fc fusion proteins were purified using Protein A chromatography. 
2.2.3.3 Transient expression of recombinant proteins in HEK293-6E cells 
All IgG molecules as well as his-tagged HER3 were expressed in suspension 
adapted HEK293-6E cells. HEK293-6E cells were cultured until exponential phase 
and a density of 1.7·106 cells/ml. For production in 100 ml cell suspension, 100 µg 
plasmid DNA and 200 µl of PEI (1 mg/ml) were each mixed with 5 ml of F17-medium. 
Both solutions were shortly vortexed and then combined. The resulting mixture was 
incubated for 15 minutes at room temperature, and carefully added to the cell 
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suspension. After 24 h incubation at 37 °C and agitation, trypton N1 (TN1) was 
added to the cells to a final concentration of 0.5 %. After further 96 hours of 
incubation at 37 °C under agitation, the cell suspension was collected and 
centrifuged (3000x g, 20 min, 4 °C). The supernatant was sterilized by filtration and 
proteins were purified as described in the following. To optimize protein purification, 
cell supernatants were optionally dialyzed against PBS prior to purification.  
2.2.3.4 Protein purification via Immobilized Metal Affinity Chromatography 
(IMAC) 
His-tagged proteins were purified via IMAC, using a batch method, where the protein 
solution is incubated with 0.5 ml of beads for at least 3 hours. All steps were carried 
out on ice and with chilled liquids. The beads were subsequently collected in a 
column and unspecifically bound proteins were washed away with at least 40 column 
volumes of IMAC wash buffer, containing 30 mM imidazole. Protein content of wash 
fractions as well as following elution fractions was determined using qualitative 
Bradford assay, where 90 µl of assay solution was mixed with 10 µl of eluted 
fractions. Blue color identified eluted protein. After washing, the specifically bound 
protein was eluted with IMAC elution buffer, containing 250 mM imidazole, in 500 µl 
fractions and main elution fractions (determined by Bradford assay) were pooled for 
dialysis against 5 l PBS overnight. 
2.2.3.5 Protein purification via protein A Affinity Chromatography 
All Fc fusion proteins and IgG molecules were purified via Protein A chromatography. 
All steps were performed on ice and with chilled liquids. The HEK293-6E supernatant 
or resuspended protein precipitate was incubated with at least 250 µl Protein A 
beads (considering the capacity of the beads, assumed protein amount and 
supernatant volume) overnight at 4 °C on a roll mixer and loaded onto a purification 
column. The beads were washed with 40 column volumes of PBS and protein 
content of the wash was determined with Bradford reagent as described above. 
Specifically bound proteins were eluted with Protein A elution buffer (10 mM glycine-
HCl pH3) and neutralized with Protein A neutralization buffer (1 M Tris-HCl pH8). 
Elution fractions were dialyzed against PBS overnight. 
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2.2.4 Protein characterization 
2.2.4.1 Determination of protein concentration 
The concentration of all proteins was determined with a spectrophotometer 
(NanoDrop), based on the absorbance of tryptophan and tyrosine residues at a 
wavelength of 280 nm. The molar extinction coefficient ε [l/(mol x cm)] and molecular 
weight (MW [g/mol]) were calculated by the online tool ‘ProtParam’ and the 
concentration was computed as follows, where b [cm] represents the path length: 
 
c [µg/ml] = OD280 x MW / (ε x b) 
 
2.2.4.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) analysis of 
purified proteins 
SDS-PAGE was performed to determine integrity and purity of the recombinant 
proteins. Dependent on the molecular mass of the proteins, gels with 8 - 12 % 
acrylamide were prepared. Protein samples were mixed with reducing or non-
reducing 5x Laemmli sample buffer and boiled for 5 minutes at 95 °C. Protein 
samples and protein standard were applied to a precast gel, which was run in SDS 
running buffer for approximately 70 minutes at 40 mA. To remove residual salt and 
detergent, the gel was washed three times in boiling water. Thereafter, the gel was 
incubated with Coomassie staining solution for at least 2 hours and destained 
overnight in water. 
 
Table 2-8: Composition of polyacrylamide gels. 
Substances  
 
Stacking Gel Separating Gel 
5% 10% 12% 
dH2O  2.1 ml 2.95 ml 2.45 ml 
30 % Acrylamide  500 µl 2.5 ml 3 ml 
1.5 M Tris, pH 8.8  - 1.9 ml 1.9 ml 
1.0 M Tris, pH 6.8  380 µl - - 
10 % SDS 30 µl 75 µl 75 µl 
10 % APS 30 µl 75 µl 75 µl 
TEMED  3 µl 3 µl 3 µl 
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2.2.4.3 Size exclusion chromatography 
High performance liquid chromatography was performed using size exclusion 
columns for the determination of purity and integrity of the purified proteins. 25 µl of 
protein sample with a concentration ranging from 0.3 to 0.5 mg/ml were injected at a 
PBS mobile phase flow rate of 0.5 ml/min. The following standard proteins were used 
for calculation of molecular mass and hydrodynamic radius: thyroglobulin (669 kDa, 
8.5 nm), apoferritin (443 kDa, 6.1 nm), bovine γ globulin (158 kDa, 5.3 nm), β-
amylase (200 kDa, 5.4 nm), bovine serum albumin (67 kDa, 3.55 nm), ovalbumin 
(44 kDa, 3.2 nm), carbonic anhydrase (29 kDa, 2.35 nm) and cytochrome c 
(12.5 kDa, 1.77 nm). 
2.2.4.4 Thermal stability measurement 
The melting point of proteins was determined by thermal denaturation via the 
ZetaSizer Nano ZS. 100 µg of recombinant protein in 1 ml PBS were sterile-filtered 
into a quartz cuvette. The temperature at which the protein starts to aggregate was 
determined by the increase of the mean count rate of dynamic laser light scattering 
and defined as the melting point. Hereby, the temperature was raised in 1 °C 
intervals from 35 to 92 °C with 2 minutes of equilibration time. 
2.2.5 ELISA 
Fc fusion proteins (300 ng/well for all binding studies, 1000 ng/well for epitope 
mapping) were coated overnight at 4 °C in ELISA plates and remaining binding sites 
were blocked with 2 percent (w/v) non-fat dry milk/PBS (MPBS). Purified proteins 
were diluted in MPBS and titrated in duplicates. Plates were washed three times in 
ELISA washing solution (0.05 % (v/v) Tween20 in 1x PBS) followed by two times 
washing with PBS. Bound proteins were detected either with HRP-conjugated anti-
human IgG (Fab specific) antibody or with HRP-conjugated anti His-tag antibody. 
Developing was performed using 100 µl of 3,3’,5,5’-tetramethylbenzidine (TMB) 
substrate per well (0.1 mg/ml TMB, 100 mM sodium acetate buffer, pH 6.0, 0.006% 
H2O2). Reaction was stopped with 1 M H2SO4 (50 µl/well) and optical density was 
measured at 450 nm in an ELISA reader. 
2.2.6 Flow cytometric analyses 
Flow cytometric studies were performed with various human cell lines. Cells were 
shortly trypsinized at 37 °C, trypsin was quenched with FCS-containing medium and 
removed by centrifugation. Cells (200.000 cells per probe) were seeded in U-bottom 
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microtiter plates and incubated with specified protein concentrations for at least one 
hour at 4 °C. Washing was performed twice with PBA (2 % (v/v) FCS, 0.02 % (w/v) 
NaN3 in 1x PBS). PE-labeled anti-human Fc antibody or PE-labeled anti-His tag 
antibody was incubated for another hour to visualize bound molecules. For the 
analysis of receptor expression, FITC-labeled goat anti-mouse antibody was 
incubated for 45 minutes, following the manufacturer’s instructions. After two further 
washing steps, the cells were resuspended in PBA and fluorescence was measured 
with a MACSQuant® Analyzer 10 or MACSQuant® VYB and median fluorescence 
intensities relative to unstained cells were calculated using the FlowJo software. 
2.2.6.1 Analysis of receptor expression 
Quantification of receptor expression was performed by indirect immunofluorescence 
staining using the QIFIKIT (Dako) according to the manufacturer's protocol and anti-
EGFR antibody (Clone AY13, diluted 1:10), anti-HER2 antibody (Clone 24D2, diluted 
1:10), and anti-HER3 antibody (Clone 1B4C3, diluted 1:10) (all mouse IgG and 
purchased from BioLegend). In brief, the kit uses beads with specified antigen 
densities to provide a standard curve, which can then be used to calculate cellular 
antigen densities. Cellular antigen amounts were detected using mouse antibodies 
applied in saturation. Comparability of fluorescence intensities is given through the 
use of the same detection antibody solution. Data analysis was performed using the 
FlowJo software, Excel and GraphPad Prism. 
2.2.6.2 Flow cytometric binding studies 
Binding of antibodies or antibody fragments to cell surface-expressed receptors was 
analyzed by flow cytometry. Target cells (Colo 205, FaDu, MCF-7 or SKBR-3) were 
treated as described above. After removal of the culture medium, the cells were 
incubated with serial dilutions of the different antibody proteins (scFv, scFv-Fc, IgG) 
in 100 µl PBA for 1 h at 4°C. Cells were centrifuged (500 g, 5 min) and washed twice 
in 150 µl PBA prior to incubating with detection antibody in 100 µl PBA. After three 
washing steps with 150 µl PBA, cells were resuspended in 150 µl PBA and analyzed. 
Relative median fluorescence intensities (MFI) were calculated using the formula: 
 relative  MFI   = (MFI!"#$%&  –   (MFI!"#"$#%&'  –   MFI!"##$)MFI!"##$  
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Following a method published by Benedict et al. 1997147, the concentration 
corresponding to half-maximal binding (EC50) was calculated from the relative MFI 
using Graphpad Prism software. 
2.2.6.3 Inhibition of heregulin binding 
MCF-7 cells were shortly trypsinized at 37 °C, trypsin was quenched with FCS-
containing medium and removed by centrifugation. Cells (200.000 cells per probe) 
were seeded and incubated with 3000 nM of IgG 3-43 or control antibody 
(cetuximab) at 4 °C. After 30 minutes, 50 nM of recombinant 6His tagged heregulin 
was added and the cells were mixed and incubated for at least another hour at 4 °C. 
Washing was performed twice with PBA (2 % (v/v) FCS, 0.02 % (w/v) NaN3 in 1x 
PBS). PE-labeled anti-His antibody (Milteny Biotec) was incubated for another hour 
to visualize bound heregulin molecules. After two further washing steps, fluorescence 
was measured with a MACSQuant® Analyzer 10 and median fluorescence intensities 
relative to unstained cells were calculated using the FlowJo software. 
2.2.7 Quarz crystal microbalance 
Affinity of the monomeric receptor ECD of HER3 and dimeric HER3-Fc fusion to IgG 
3-43 was determined via quartz crystal microbalance measurements using an Attana 
Cell 200 instrument. IgG 3-43 was immobilized on the surface of a low nonspecific-
binding carboxyl chip using the amine coupling kit (EDC + sNHS, Attana AB, 
Stockholm, Sweden) in a density that resulted in a frequency change of about 90 Hz. 
The measurement was performed at 25 °C with a flow-rate of 25 µl/min of PBST 
(0.1 % Tween) pH 7.4. Regeneration of the binding was performed twice with 3 M 
MgCl2 for 15 seconds. After every second measurement a buffer injection was 
performed to determine the baseline, which was subsequently subtracted from the 
measurements. Soluble His-tagged HER3 was injected in a two-fold dilution series in 
PBST in random order, with concentrations between 1.25 to 20 nM. Dimeric HER3-
Fc was injected in a two-fold dilution series in PBST in random order, with 
concentrations between 0,625 to 10 nM. Data were analyzed with the Attana 
evaluation software and TraceDrawer. 
Affinity of scFv 2-35 to HER2-Fc was measured using an Attana A200 instrument. 
HER2-Fc was immobilized on the surface of a low nonspecific-binding carboxyl chip 
using the amine coupling kit (EDC + sNHS, Attana AB, Stockholm, Sweden) in a 
density that resulted in a frequency change of about 100 Hz. The measurement was 
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performed at 25 °C with a flow-rate of 25 µl/min of PBST (0.1 % Tween) pH 7.4. 
Regeneration of the binding was performed twice with Glycin-HCL pH 3 containing 
15 mM NaCl for 12 seconds. After every second measurement a buffer injection was 
performed to determine the baseline, which was subsequently subtracted from the 
measurements. ScFv 2-35 was injected in a two-fold dilution series in PBST in 
random order, with concentrations between 32 to 512 nM. Data were analyzed with 
the Attana evaluation software and TraceDrawer using a monophasic fit. 
2.2.8 Immunoblotting 
SDS polyacrylamide gel electrophoresis as first described 1970 by Laemmli148 was 
performed to separate the proteins of the cell lysates. Protein samples were mixed 
with reducing 5x Laemmli sample buffer and boiled for 5 min at 95 °C. Protein 
samples and protein standard were applied to a gradient gel and let run according to 
the manufacturer’s instructions. Protein bands were transferred to nitrocellulose or 
PVDF membranes using the iBlot 2 device. Further analysis and sample preparation 
is described in the following.  
For immuno-blotting of purified proteins, the standard procedure and self-made gels 
as described in 2.2.4.2 were used and protein fractions were transferred to 
nitrocellulose membrane using a semi-dry blotter. Blocking was performed in 2% 
MPBS at room temperature for one hour and detection antibodies were incubated in 
2% MPBS for at least three hours. Washing was performed twice with western 
washing solution (PBST) for 5 minutes and once with PBS for another 5 minutes. 
HRP couple antibodies were detected with ECL substrate and visualized by the 
FUSION SOLO Imager. 
2.2.8.1 Immunoblotting for analyses of signaling pathways 
Cells were grown in 6-well plates (2·105 cells per well) overnight and then starved in 
medium containing 0.2 % FCS for another day. Next, cells were incubated with 
indicated concentrations of antibodies in starvation medium at 37 °C for 1 hour or the 
indicated time. Subsequently, cells were stimulated with heregulin (50 ng/ml) for 
15 minutes, before being lysed using protease inhibitor containing RIPA buffer 
(50 mM Tris (pH 7.5), 150 mM NaCl, 1 % Triton-X 100, 0.5 % sodium deoxycholate, 
0.1 % SDS, 1 mM sodium orthovanadate, 10 mM sodium fluoride and 20 mM β-
glycerophosphate plus Complete protease inhibitors (Roche, Basel, Switzerland) at 
4 °C. Lysates were centrifuged (13,200 rpm, 30 minutes, 4 °C) and supernatants 
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were collected. Protein concentrations in each lysate were assessed using the Bio-
Rad DC™ Protein Assay. Lysates were fractionated by SDS-PAGE and transferred 
onto nitrocellulose membranes (iBlot®Gel Transfer Stacks; Invitrogen) using the 
iBlot® 2 Dry Blotting System. Membranes were blocked with 0,5 % blocking reagent 
(Roche) in PBS containing 0.1 % Tween-20 and incubated with indicated primary 
antibodies overnight at 4 °C, followed by five washing steps with 0.5 % PBST and 
incubation with HRP-conjugated secondary antibody for 1 hour at room temperature. 
After washing, activity of HRP was detected with ECL substrate and visualized by the 
FUSION SOLO Imager. Quantification of band intensities was performed using the 
FUSION Software and Microsoft Excel. All values were normalized to the 
corresponding loading control. 
2.2.8.1.1 Analysis of concentration dependent protein phosphorylation 
Cells were treated as described in 2.2.8.1. Serial antibody dilutions were incubated 
with the indicated cells in starvation medium at 37 °C for 1 hour. Lysate preparation 
and analyses was performed as described above (2.2.8.1). The half maximal 
inhibitory concentration was calculated using GraphPad Prism software. 
2.2.8.1.2 Analysis of HER3 degradation 
Cells were treated as described in 2.2.8.1. 100 nM IgG 3-43 or control antibody 
(Atrosab) were incubated with MCF-7 cells in starvation medium at 37 °C for 
5 minutes, 1, 2, 4 or 6 hours. Lysate preparation and analyses was performed as 
described above (2.2.8.1). HER3 receptor was stained with ErbB3 clone 2F12 
antibody (Thermo scientific) and detected using HRP-coupled secondary antibody 
and ECL substrate. 
2.2.9 Cy5-Labeling of IgG 
For direct protein labeling with fluorescent Cy5 reagent, Amersham Cy5 malemide 
mono-reactive dye was used according tot he manufacturer’s instructions. Briefly, 
1 mg of protein was dissolved in 1 ml room tempered degassed PBS and left at room 
temperature for 30 minutes. A 100 molar excess of TCEP was added (here, 10 µl of 
an 18 mg/ml TCEP solution in PBS was used). Before and after addition of TCEP, 
the reaction tube was flushed with nitrogen gas. The vial was capped, mixed and 
incubated at room temperature for 10 minutes. Meanwhile, the dried labeling dye was 
dissolved in 50 µl anhydrous Dimethylformamide, also flushed with Nitrogen gas and 
mixed. The dye solution was then added to the reduced protein. The tube was 
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flushed with Nitrogen gas again, mixed and incubated at room temperature for two 
hours while mixing every 30 minutes. The reaction was left over night at 2-8 °C. On 
the next day, the labeled antibody was separated from unconjugated dye by gel 
permeation chromatography with a PD-10 Desalting column (also from GE 
Healthcare). For the estimation of dye to protein ratio, absorbance of dye at 650 nm 
and protein at 280 nm was measured and divided through the according extinction 
coefficients. The dye absorbance at 250 nm was assumed to be 5 percent of the 
absorbance at 650 nm and was subtracted from the protein absorbance.  
2.2.10 Receptor internalization 
MCF-7 cells were seeded on 8-well glass chamber slides (BD) one day before the 
experiment to be semi-confluent on the next day (104 cells per sample). Cy5 labeled 
IgG 3-43 was incubated in growth medium at 37 °C for the indicated time periods 
(5 minutes, 1 hour or 2 hours, or 1 minute at room temperature as binding control 
(referred to as 0 min sample). The cells were fixed with 4 % PFA in PBS (200 µl/well) 
for 15 minutes at 37 °C. Fixed cells were washed with PBS and counterstained with 
Concanavalin A and DAPI for 10 minutes. After three more washing steps with PBS, 
the cells were mounted with Fluoromunt G and covered with cover slips. Dried slides 
were stored at 4 °C and the experiment was performed on a Zeiss Axio Observer 
Spinning Disc microscope equipped with a Plan-Apochromat 10x/0,45 M27 objective 
and an Axiocam 503 mono CCD camera. The following excitation lasers and 
emission filters were used: DAPI: 405 diode laser, 450/50 nm filter; GFP: 488 nm 
diode laser, 525/50 nm filter; RFP: 561 nm (RFP) diode laser, 600/50 nm filter; Cy5: 
638 nm, 690/50 nm filter. Images were analyzed with the ZEN software (Zeiss). 
2.2.11 Three-dimensional oncogenic K-Ras model  
Caco-2tet RasG12V cells were generated before the start of this thesis as described in 
Möller et al., 2014149 and kindly provided by Dr. Tilman Brummer and Prof. Monilola 
Olayioye. The cells were seeded on a bed of growth factor reduced matrigel (BD) 
and PureCol-S collagen (Advanced Biomatrix, San Diego, CA, USA) (mixed 1∶1) and 
overlayed with growth medium containing 2 % matrigel. Expression of oncogenic K-
RasG12V was induced one day post seeding with 2 µg/ml doxycycline. 100 nM IgG 3-
43 or control antibody (Rituximab) or 200 nM pan-ErbB inhibitor AZD8931 was also 
applied one day post seeding. Lumen expansion was induced by addition of 
100 ng/ml choleratoxin (CTX; Sigma Aldrich) at day 3 post seeding. Five days’ post 
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seeding, the cells were fixed with 4% PFA for 15 min, permeabilized with PBS 
containing 0.1 % Triton X-100 for 10 minutes and blocked with 5 % goat serum 
(Invitrogen) in PBS containing 0.1% Tween-20. Cells were then incubated with 
primary antibodiy (anti-E-cadherin 1:200) in blocking buffer (2 hours at RT), washed 
with PBS containing 0.1 % Tween-20 and incubated with secondary antibody (anti-
rabbit AF 633) in blocking buffer (2 hours at RT). F-Actin and nuclei were 
counterstained with Alexa Fluor 546-labeled phalloidin and DAPI. Slides were 
mounted in Fluoromount G and analyzed on a confocal laser scanning microscope 
(LSM 700; Zeiss, Oberkochen, Germany) using 488, 561 and 633 nm excitation with 
oil objective lenses Plan-Apochromat 63x/1.40 DIC M27. Images were processed 
with the ZEN software (Zeiss). To determine the number of cysts with a ‘predominant 
single apical lumen’, spheroids were analyzed in terms of roundness, cell-free lumen 
formation and F-actin staining of the apical surface. 
2.2.12 Proliferation assays 
1·103 cells per well were grown in 100 µl growth medium containing 10 percent FCS 
in 96-well plates at 37 °C for one day. Then, cells were incubated with the indicated 
concentrations of antibodies in reduced serum medium (0.2 % FCS) at 37 °C for 6 
days in the presence or absence of 10 ng/ml heregulin. Next, the number of viable 
cells was determined using the Cell-Counting-Kit-8. The absorbance at 450 nM was 
measured in an ELISA reader. 
2.2.13 In vivo assays 
Animal care and all experiments performed were in accordance with federal 
guidelines and have been approved by university and state authorities.  
2.2.13.1 Pharmacodynamics 
FaDu cells were freshly thawed and expanded in the absence of 
Penicillin/streptomycin in growth medium. 5*106 cells were injected subcutaneously 
into both flanks of female SCID Beige mice.  For this purpose, adherent cells were 
detached from the culture flasks using working solution of trypsin/EDTA and 
resuspended in 50 ml culture medium. The cells were counted and harvested (500x 
g, 5 minutes, 4 °C), washed with 50 ml 1x PBS and pelleted again. Finally, the cells 
were resuspended in 1x PBS adjusting cells per ml in 1x PBS. During the injection of 
the cells, the mice were anesthetized with isoflurane. As soon as the tumors were 
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palpable, tumor sizes were measured every second day with calipers. Tumor 
volumes were calculated using the formula  
 Tumor  volume = a ∗ b²2  
 
with a= longitudinal diameter of tumor and b= transverse diameter of tumor. 
Treatment started when tumors reached a volume of approximately 80 mm3 (14 days 
after tumor cell inoculation). Mice received twice weekly intravenous injections for 3 
weeks (q2wx3) at doses of 30, 100, and 300 µg, including PBS as negative control 
(on day 14, 17, 21, 24, 28 and 31).  
2.2.13.2 Pharmacokinetics 
Three animals of each treatment group of the pharmacodynamics experiment 
described in 2.2.13.1 (twice weekly injections with either 30 µg, 100 µg or 300 µg 
IgG 3-43 for three weeks) were used to determine serum half-life of IgG 3-43. Blood 
samples (around 50 µl) were collected from the tail in the time intervals of 3 minutes, 
1 hour, 1 day, and 3 days after the first (day 14) and 3 minutes, 1 hour, 1 day, 3 days 
and one week after the last (day 32) antibody injection and incubated on ice for at 
least 10 minutes. Clotted blood was centrifuged (13,000 g for 30 min at 4 °C) and 
serum samples were stored at -20 °C. IgG serum concentration was analyzed by 
ELISA as described above using 300 ng/well HER3-Fc for coating and HRP coupled 
anti human IgG (Fab-specific) antibody diluted 1:20 000 for detection by interpolation 
from a standard curve of purified IgG 3-43. Initial and terminal half-lives (t1/2α, t1/2β) 
and AUC were calculated with Excel. Initial half-lives were calculated over the time 
interval of 3 min to 24 h. Terminal half-lives were calculated with the last three serum 
concentrations (1h-72h or 24h -168h). 
2.2.13.3 ALT assay 
Three animals of each treatment group of the pharmacodynamics experiment 
described in 2.2.12.1 (twice weekly injections with either 30 µg, 100 µg or 300 µg IgG 
3-43 for three weeks) were used to determine potential liver toxicity of IgG 3-43. 
Blood samples were taken 24 hours after the last injection and incubated on ice for at 
least 10 minutes. Clotted blood was centrifuged (13,000 g for 30 min at 4 °C) and 
serum samples were stored at 4 °C. 5 µl of serum and Alanine Transaminase Activity 
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Assay kit were used according to the manufacturer’s instructions to determine ALT 
activity in the samples.  
2.2.14 Statistical analysis 
In vitro values are shown as mean with the corresponding standard deviation. The 
tumor volumes of the in vivo experiment are displayed with mean and 95 % 
confidence interval. Significances were calculated with GraphPad Prism using one-
way Anova with Tukey’s post-test or unpaired t-test. * represents a p-value below 
0.05, ** below 0.01 and *** below 0.001. 
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3 Results 
3.1 Quantitative analysis of ErbB receptor expression  
Receptors of the EGFR family are important regulators of cellular growth and are 
required for the survival of many cancer cells. To assess the therapeutic potential of 
antagonistic EGFR family receptor-targeting monoclonal antibodies, different cancer 
cell lines were quantified by indirect immunofluorescence staining for EGFR, HER2, 
and HER3 expression levels (Table 3-1). The analyzed cell lines express moderate 
to low levels of HER3, with the highest levels detected in the breast cancer cell lines 
MCF-7, SKBR-3 and BT-474. In contrast, very high levels of EGFR (A431) and HER2 
(BT-474, SKBR-3, NCI-N87) were measured in some cell lines, with values above 
1.000.000 receptors per cell, which lies beyond the quantification scale of the used 
kit (572.000 molecules/cell). 
 
 
Figure 3-1: ErbB receptor expression of cancer cell lines 
Expression of HER receptors was analyzed by FACS using mouse primary antibodies and Dako’s 
QIFIKIT. Mean values of 2-4 independent experiments ± SD are shown. 
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Table 3-1: Important characteristics of cancer cell lines used in this study 
Quantitative expression of the ErbB family members EGFR, HER2 and HER3 was measured using 
Dako’s QIFIKIT. Average numbers of receptors per cell obtained from at least (except BT-474) three 
independent measurements are listed. Important cancer driving mutations were listed in the last 
column (mut.). Mutations directly concerning ErbB receptor downstream signaling pathways are 
shown in bold. 
cancer type cell line origin EGFR HER2 HER3 mut. 
breast 
BT-474 
ductal 
carcinoma 
(mammary 
gland) 
7,200 >572,000 11,200 PIK3CA, TP53 
MCF-7 
adenocarcinoma 
(mammary 
gland) 
<1,900 21,200 17,300 CDKN2A, PIK3CA 
SKBR-3 
adenocarcinoma 
(mammary 
gland) 
29,800 >572,000 14,100 TP53 
colon 
Caco-2 colorectal adenocarcinoma 4,400 15,100 4,700 
APC, 
SMAD4 
Colo 205 colorectal adenocarcinoma 4,300 23,800 2,900 
APC, 
BRAF, 
SMAD4, 
TP53 
HCT-116 colorectal carcinoma 18,600 5,700 <1,900 
CDKN2A, 
KRAS, 
PIK3CA, 
epithelial A431 epidermoid carcinoma >572,000 8,700 4,400 TP53 
gastric NCI-N87 stomach 16,200 >572,000 3,300 SMAD4, TP53 
head and 
neck FaDu 
squamous cell 
carcinoma 
(pharynx) 
143,300 15,800 2,900 
CDKN2A, 
SMAD4, 
TP53 
lung A549 lung carcinoma 64,100 6,400 <1,900 CDKN2A, KRAS 
ovarian SKOV-3 adenocarcinoma (ovary, ascites) 43,500 54,400 <1,900 
SMAD4, 
TP53 
 
3.2 Screening of newly isolated HER2 receptor antibody 
binding sites for potential drug components 
HER2 is a potent oncogene150 overexpressed in many human cancer types. In order 
to generate new antibody binding sites targeting and preferably also inhibiting this 
receptor, a panel of anti-HER2 scFv (2-31 – 2-37) was isolated from a human 
antibody phage library by selection against a human HER2ECD-Fc fusion (aa 23-652) 
protein prior to this thesis. After production in TG1 E. coli cells and purification via 
IMAC, the proteins were analyzed with respect to productivity, purity and antigen and 
cell binding capacity. The obtained results are listed in Table 3-2. 
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Table 3-2: Yields and binding data of the 7 selected scFvs. 
Binding to human HER2-Fc was analyzed by ELISA (n=3; mean ± SD). Binding to SKBR-3 cells was 
analyzed by flow cytometry (n=1). 
scFv yield (in mg/l) ELISA (EC50 in nM) cell binding (EC50 in nM) 
4D5 N/A 2,6 ± 1,1 3.0 
2-31 0,2 28,6 ± 21,3 20.9 
2-32 1,3 384,3 ± 523,1 n/a 
2-33 0,2 24,9 ± 17,0 4.0 
2-34 0,2 11,1 ± 2,9 7.3 
2-35 0,2 4.2 ± 2.8 5.5 
2-36 0,3 12,3  ± 17,3 - 
2-37 0,2 91,3  ± 127,4 - 
 
All scFv proteins migrated in good correlation to the calculated molecular weight of 
around 30 kDa through polyacrylamide gels during electrophoresis (Figure 3-2 A, B). 
The antigen binding capacities were analyzed via ELISA using immobilized Fc fusion 
protein of the extracellular domain of HER2 (Figure 3-2 C). The proteins bound to 
HER2-Fc with EC50-values in the nanomolar range. The lowest determined EC50 of 
4.2 nM was revealed by scFv 2-35. Five of the seven clones bound to cellular HER2 
on SKBR-3 cells, as analyzed by flow cytometry (Figure 3-2 D). Sequence analysis 
revealed a high similarity between scFv 2-34 and scFv 2-35. To further examine 
weather this sequence similarity, which was observed in all HER2 binding clones, 
albeit to a lesser extend, translates in biological consistency in terms of epitope 
similarity, another flow cytometric experiment was performed using the dimeric scFv-
Fc fusion proteins of scFv 2-31, 2-33 and 2-35 (further analysis of the produced 
scFv-Fc fusion proteins is described in chapter 3.3). SKBR-3 cells were preincubated 
with the HER2 binding scFv proteins or a HER3 binding scFv as control (scFv 3-43, 
described in chapter 3.5), and binding of the prebound cellular HER2 by scFv 2-35-
Fc was analyzed. This experiment is shown in Figure 3-3 and revealed, that scFv 2-
31, scFv 2-33 and scFv 2-35 competed for closely located, overlapping or even the 
same epitopes on HER2. Therefore, only scFv 2-35, which had the highest affinity for 
HER2 as analyzed via ELISA, flow cytometry using SKBR-3 cells and quartz crystal 
microbalance, was chosen for further analysis and IgG construction. 
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Figure 3-2: Analysis of HER2 binding scFv proteins 
A, B SDS-PAGE analysis of the purified HER2 binding scFv proteins 2-31 (1), 2-32 (2), 2-33 (3), 2-34 
(4) and 2-35 (5) under reducing (A) and non-reducing (B) conditions. C Binding of the scFv proteins to 
recombinant HER2 was investigated by ELISA. Serial dilutions of the scFv proteins were applied to 
immobilized Fc tagged HER2 on ELISA plates. The scFv proteins were detected via HRP coupled 
anti-His-tag antibody (n=3 ; mean ± SD). D Binding to cellular HER2 was analyzed by Flow cytometry. 
100 nM of the scFv proteins were incubated with detached SKBR-3 cells for two hours in the dark at 
4°C. The cells were washed twice before the bound scFv protein was detected with PE coupled anti-
His-tag antibody.  
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Figure 3-3: Epitope redundancy of scFv 2-32, scFv 2-33 and scFv 2-35.  
Overlapping epitopes of the three scFv proteins 2-31, 2-33 and 2-35 were demonstrated by Flow 
cytometry. SKBR-3 cells were incubated with the indicated scFv antibodies and washed twice before 
incubation with scFv 2-35-Fc fusion protein. Detection of bound scFv 2-35-Fc was performed using PE 
coupled anti-human Fc antibody. One representative of two independent experiments is shown with 
mean of double values ± SD. 
 
Size exclusion chromatography was performed to determine the hydrodynamic 
radius and protein integrity of scFv 2-35 under native conditions (Figure 3-4 A). The 
main peak eluted at 19.1 minutes, which corresponds to an estimated molecular 
mass of 35.5 kDa. An earlier peak with a main fraction eluted at 16.8 minutes, 
corresponding to an estimated molecular mass of 65.1 kDa and most likely 
accounting to protein dimer was also observed. The aggregation point of scFv 2-35 
was determined by dynamic light scattering to 44 °C (Figure 3-4 B). ScFv 2-35 did 
not bind to the extracellular domain of mouse HER2 as analyzed via ELISA using 
recombinant protein consisting of the extracellular domain of mouse HER2 fused to a 
human Fc part (Figure 3-4 C). Affinity measurements employing quartz crystal 
microbalance revealed a KD of 24.8 nM for the binding of scFv 2-35 to dimeric HER2-
Fc (Figure 3-4 D). Titration of scFv 2-35 on HER2 overexpressing SKBR-3 cells and 
further flow cytometric analysis revealed an EC50 of 5.5 nM for the binding of cellular 
HER2 (Figure 3-4 E). 
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Figure 3-4: Analysis of biochemical integrity and binding characteristics of scFv 2-35  
A Purity and integrity of scFv 2-35 was analyzed via size exclusion chromatography using a Yarra 
SEC-2000 column. Dashed lines represent the retention time of standard proteins with their molecular 
masses indicated above the lines. Main peek: 19,4 min B The aggregation point of scFv 2-35 was 
determined via dynamic light scattering. The measured aggregation point is indicated by a dotted line. 
C Binding to mouse HER2 was measured using ELISA technique. Recombinant mouse HER2 or 
human Fc tagged HER2 were immobilized to ELISA plates. 100 nM of scFv 2-35, scFv 4D5 
(reference) or HER3 binding scFv 3-43 (negative control) were added and detected with HRP coupled 
anti-His-tag antibody. Coating was detected using HRP coupled anti-Fc antibody. Shown are means of 
double values with standard deviations. D Affinity of scFv 2-35 to HER2-Fc was measured in a QCM 
approach. Two-fold serial dilutions of scFv 2-35 starting from 512 nM were injected in random order 
into the Attana system. The measurement was performed at pH7.4. Three binding curves were 
measured for each concentration and fitted using TraceDrawer software (black). E Binding to cellular 
HER2 was analyzed by Flow cytometry using the HER2 overexpressing breast cancer cell line SKBR-
3. Serial dilutions of scFv 2-35 were added to the detached cells. Binding of scFv 2-35 was detected 
with PE conjugated anti-His-tag antibody. Mean values of three independent experiments with 
standard deviations are shown. 
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3.3 Dimeric scFv-Fc fusion proteins comprising the new 
HER2 antibody binding sites  
The four scFv proteins scFv 2-31, scFv 2-33, scFv 2-35 all showed high affinity to 
their cellular expressed antigen HER2. However, scFv proteins are very small and 
unstable. In order to create dimeric proteins of higher molecular mass and stability, 
scFv-Fc fusion proteins were established from the respective scFv plasmids. ELISA 
using HER2-Fc, and flow cytometry using SKBR-3 cells for the anti-HER2 scFv-Fc 
fusion proteins revealed EC50 values for antigen and cell binding in the low 
nanomolar range (Table 3-3) confirming an avidity effect for dimeric antibody 
molecules comprising the selected binding domains.  
 
Table 3-3: Production yields and binding data of HER2 binding scFv-Fc fusion proteins 
Half maximum binding in ELISA was measured using immobilized HER2-Fc protein and HRP coupled 
anti-His tag antibody for detection; n=2. Cell binding of scFv-Fc fusion proteins to SKBR3 was 
measured using flow cytometric analysis. Binding was detected via PE conjugated anti-human-Fc 
antibody; n=3.  
scFv-Fc yield (in mg|l) 
ELISA 
(EC50 in nM) 
cell binding 
(EC50 in nM) 
2-31 6.4 1.4 1.9 
2-33 3.0 1.8 0.9 
2-35 4.2 0.9 0.7 
 
The scFv-Fc fusion proteins migrated through polyacrylamide during electrophoresis 
with speeds corresponding to the calculated molecular weights. The double bands 
seen in Figure 3-5 B most likely refer to the glycosylated and unglycosylated forms of 
the fusion proteins. However, although the proteins looked pure and integer on SDS-
PAGE analysis and bound specifically to their respective antigen as seen in Figure 
3-5 D, size exclusion chromatography revealed no exclusive peaks for all of these 
fusion proteins (Figure 3-5 C). To get one integer antibody with not only high affinity 
cell binding properties, but also good effector functions enabling immune cell 
recruiting, the VH and VL domains of scFv 2-35 were in the next part of the thesis 
used for generation of IgG1 molecules. 
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Figure 3-5: ScFv-Fc fusion proteins derived from selected HER2 and HER3 binding scFv 
A Schematic illustration of the scFv-Fc fusion proteins. Dimerization is achieved by the Fc part. B 
Coomassie stained SDS-PAGE analysis of scFv-Fc proteins under reducing (left, 1-3) and non-
reducing (right, 4-6) conditions. 1,4: scFv 2-31-Fc. 2,5: scFv 2-33-Fc. 3,6: scFv 2-35-Fc. M: protein 
standard marker. C Size exclusion chromatography of HER2 binding scFv-Fc proteins. D ELISA using 
immobilized HER2-Fc and HER3-Fc (receptor specificity control) to investigate antigen binding of the 
scFv-Fc proteins. Bound scFv-Fc proteins were detected via HRP coupled anti-His tag antibody. 
HER3 binding scFv 3-43-Fc served as negative control; n=1 (double values, mean ± SD). 
 
3.4 Fully humanized IgG 2-35 
To create a potent anti-cancerous drug candidate, scFv 2-35 was converted into 
IgG1. As a reference, IgG 2-35 was compared with the clinically well-established 
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antibody Trastuzumab. To improve ADCC of IgG 2-35, two amino acid substitutions 
(S239D/I332E) were introduced into the human Fc domain (referred to as SI) as 
described by Horton et al. in 2008151. From one liter of HEK293-6E supernatant 66 
mg IgG 2-35 could be purified by protein A chromatography. In the following, IgG 2-
35 was analyzed in respect of its purity, integrity, and thermal stability. Functional 
analysis included binding to HER2 expressing cancer cells as well as the 
examination of its growth inhibiting potential.  
3.4.1 Biochemical analysis of IgG 2-35 
SDS-PAGE analysis of IgG 2-35 under non-reducing conditions exhibited a single 
band at a height being in good correlation to the calculated molecular weight of 149.2 
kDa, corresponding to the dimeric whole antibody. Under reducing conditions, two 
bands occurred, corresponding to the monomeric single heavy chain around 50 kDa 
and the smaller light chain around 25 kDa. In size exclusion chromatography, IgG 2-
35 appeared as a single narrow peak eluted shortly after the 200 kDa standard 
protein. The weight estimated from the hydrodynamic radius revealed in this 
measurement was 186.6 kDa. This slightly bigger hydrodynamic radius was also 
observed for other IgG molecules and presumably accounts to glycosylation. 
Trastuzumab, which was run on the same day on the same column was estimated to 
have a molecular weight of 202.5 kDa. Dynamic light scattering measurement 
revealed that the protein was stable up to a temperature of 68 °C.  
 
A 
 
B 
 
C  
 
Figure 3-6:Biochemical characterization of IgG 2-35 
A SDS-PAGE analysis of IgG 2-35 under non-reducing (line 1) and reducing (line 2) conditions. B Size 
exclusion chromatography of IgG 2-35 using a Yarra SEC-2000 column. (186,6 kDA hydrodynamic 
radius) C Determination of the aggregation point of IgG 2-35 was performed using dynamic light 
scattering. The measured aggregation point is indicated with a dotted line. 
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3.4.2 Binding property of IgG 2-35 
ELISA using HER2-Fc revealed an EC50 of 350 pM for HER2-ECD binding of IgG 2-
35. In flow cytometric analysis, IgG 2-35 bound with EC50 of 330 pM and 200 pM to 
SKBR-3 and Colo 205 cells, respectively. According to these measurements, binding 
capacity of IgG 2-35 is superior to Trastuzumab, which bound in the same assays 
with EC50 of 490 pM, 2.5 nM and 500 pM, respectively (not shown). 
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Figure 3-7: Binding characteristics of IgG 2-35 
A Binding of IgG 2-35 to recombinant HER2 was analyzed by ELISA using HRP coupled Fab-specific 
anti-human IgG antibody for detection of the bound IgG. (EC50: 346 pM) B, C Binding of IgG 2-35 to 
cellular HER2 was analyzed by Flow cytometry using HER2 overexpressing SKBR-3 (B) cells (EC50: 
327 pM) and Colo 205 (C) (EC50: 200 pM). Bound IgG was detected using PE conjugated anti-human 
Fc antibody. A,B,C: n=3, ± SD. 
 
3.4.3 IgG 2-35 decelerates growth of HER2 expressing cancer cell 
lines in vitro  
A good binding capacity is a favored characteristic of therapeutic antibodies. 
However, strong binding to growth receptors does not necessarily translate in 
antiproliferative activity. To monitor the growth inhibiting potential of IgG 2-35, 
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proliferation assays using the HER2 overexpressing breast and gastric cancer cell 
lines BT-474 and NCI-N87 were performed. For BT-474, presence of IgG 2-35 
reduced the EGF stimulated growth and led to reduction of 40 % in cell count. 
Trastuzumab also led to a reduction in cell count after six days, but only about 20 %. 
EGFR binding cetuximab served as positive reference and also led to reduced 
proliferation of BT-474 cells in the presence of EGF. For NCI-N87, both Trastuzumab 
and cetuximab led to a 20 % reduction of living cells after six days. Here, IgG 2-35 
was significantly superior with only less than 60 percent of the cell amount in the 
control antibody incubated wells present. However, for SKBR-3 cells incubated in 
normal growth medium in the absence of EGF, no growth inhibiting effect of IgG 2-35 
(up to 3 µg/ml) could be observed, while the same amount of trastuzumab inhibited 
SKBR-3 proliferation (data not shown). 
 
A 
 
B 
 
Figure 3-8: Proliferation inhibiting function of IgG 2-35 
A Semi confluent proliferating BT-474 breast cancer cells were detached and diluted to 10.000 cells 
per ml. 100 µl of the cell suspension was pipetted in the wells of a 96 well cell culture plate. After 24 
hours’ adhesion time 10 µg/ml of the indicated IgG molecules were added to the cells in low FCS but 
10 ng/ml EGF containing culture medium. After seven days, the experiment was stopped and the 
amount of viable cells was measured using CCK-8 cell viability kit. The obtained absorbance values 
were normalized to cells treated with an irrelevant control IgG (Atrosab). B The same experiment like 
in A was performed using the gastric cancer derived cell line NCI-N87. A, B: n=3, mean ± SD. 
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3.5 Screening of scFv proteins for a high affinity HER3 
binder 
A panel of anti-HER3 scFv was isolated from a human antibody phage library by 
selection against a human HER3-Fc fusion protein (aa 20-643) prior to this study. 
The production yields were located between 0.2 and 2.9 mg per liter cell suspension. 
In SDS-PAGE analysis, all scFv proteins appeared as single bands at heights 
corresponding to the calculated molecular weights (around 30 kDa for all scFv 
proteins) (Figure 3-9). All eight clones showed binding to HER3-Fc in ELISA with 
EC50 in the nanomolar range (shown in Figure 3-10 and Table 3-4) and were further 
analyzed for binding to HER3-expressing MCF-7 cells by flow cytometry. Here, one 
of the clones showed particularly strong cell binding. This clone, scFv 3-43, also 
depicted the best production yields and lowest EC50 in ELISA between the analyzed 
clones. Furthermore, it also showed better binding performance than scFv 3M6, 
which was derived from the variable domains of the currently clinically tested 
Seribantumab (MM-121), comprising one stabilizing mutation (Cys89Ser) and 
connected via a flexible G4S-linker, and served as reference. Therefore, scFv 3-43 
was chosen as candidate for further development and was thoroughly analyzed in 
the following.  
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Figure 3-9: SDS-PAGE analysis of the purified HER3 binding scFv proteins 
SDS-PAGE (Coomassie stained) under reducing (A) and non-reducing (B) conditions analyzing scFv 
3-38 (lane 1), scFv 3-39 (lane 2), scFv 3-40 (lane 3), scFv 3-41 (lane 4), scFv 3-42 (lane 5), scFv 3-43 
(lane 6), scFv 3-44 (lane 7) and scFv 3-45 (lane 8) (M, protein standard marker). 
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Figure 3-10: HER3 binding of scFv proteins 
A Binding of the scFv proteins to HER3 was investigated by ELISA. Serial dilutions of the scFv 
proteins were added to immobilized Fc tagged HER3 on ELISA plates. The scFv proteins were 
detected by HRP coupled anti-His-tag antibody. Shown are mean values of n=3 ± SD. B Binding of 
the scFv proteins to cellular HER3 was analyzed by Flow cytometry using HER3 expressing MCF-7 
human breast cancer cells. 100 nM of the indicated scFv proteins were incubated with the detached 
cells and bound scFv was detected via PE conjugated anti-His-tag antibody (mean of double values ± 
SD). 
 
Table 3-4: Yields and binding data of the 8 selected scFvs. 
Binding to human HER3-Fc was analyzed by ELISA. Binding to MCF-7 cells was analyzed by flow 
cytometry. 
scFv yield (in mg|l) 
ELISA 
(EC50 in nM ± SD) 
cell binding 
(EC50 in nM ± SD) 
3M6 0.4 7.6 ± 3.5 3.3 ± 1.3 
3-38 1.3 9.9 ± 1.1 n/a 
3-39 1.2 5.8 ± 1.6 8.5 
3-40 0.4 88.4 ± 1.7 n/a 
3-41 0.5 3.4 ± 1.3 n/a 
3-42 0.5 56.8 ± 22.3 n/a 
3-43 2.9 3.5 ± 2.8 0.7 ± 0.3 
3-44 2.4 11.4 ± 0.6 7.6 
3-45 0.2 42.4 ± 8.8 n/a 
 
ScFv3-43 showed a clearly dominating peak in HPLC-SEC at 18.9 minutes, 
corresponding to a hydrodynamic radius that correlated to an estimated molecular 
weight of 38.7 kDa, which is in good accordance to the calculated MW of 31.1 kDa. 
An aggregation temperature of scFv 3-43 of 58 °C was determined by dynamic light 
scattering. Moreover, scFv3-43 bound in addition to human HER3-Fc also to its 
mouse counterpart, however, with a slightly reduced EC50 value, meaning that scFv 
A  
 
B 
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3-43 binds to a conserved epitope on HER3 (Figure 3-11 C). Human HER3, 
expressed on the surface of MCF-7 cells was bound by scFv 3-43 with an EC50 value 
of 700 pM as determined by Flow cytometry (Figure 3-11 D). 
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Figure 3-11: Characterization of scFv 3-43 
A 25 µl of scFv 3-43 was analyzed for its purity and integrity via size exclusion chromatography on a 
Yarra SEC-2000 column, with PBS as liquid phase. Dashed lines represent the retention time of 
standard proteins with their molecular masses indicated above the lines. Main peek: 18,9 min. B The 
aggregation point of scFv 3-43 was determined via dynamic light scattering. The measured 
aggregation point is indicated by a dotted line. C Binding to mouse HER3 was tested by ELISA. 
Recombinant mouse HER3 or human Fc tagged HER3 were immobilized to ELISA plates. 100 nM of 
scFv 3-43, scFv 3M6 (reference) or HER2 binding scFv 4D5 (negative control) were added and 
detected with HRP coupled anti-His-tag antibody. n=2. Shown are double values of one representative 
experiment ± SD. D Binding to cellular HER3 was analyzed by Flow cytometry using the HER3 
expressing breast cancer cell line MCF-7. Serial dilutions of scFv 3-43 were added to the detached 
cells. Binding of scFv 3-43 was detected with PE conjugated anti-His-tag antibody; n=3, mean ± SD. 
 
The scFv 3-43 was further analyzed in immunoblotting experiments for binding to 
reduced and non-reduced HER3-Fc. The experiment shown in Figure 3-12 indicated 
a complex epitope for scFv 3-43 on HER3 that is reduction sensitive, meaning that it 
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does not recognize only the primary amino acid sequence, but needs a correct 
spatial conformation for binding. 
 
A  
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Figure 3-12: Analysis of scFv 3-43 for binding to reduced and non-reduced HER3-Fc. 
A Coomassie stained SDS-PAGE of HER3-Fc under reducing (r) and non-reducing (nr) conditions. B 
Immunoblot analysis of reduced HER3-Fc (5 µg per lane) for binding of scFv 3-43. An anti-Fc antibody 
was included as a positive control. ScFv 3-43 was detected via HRP coupled anti-His antibody. HER3-
Fc was detected via HRP coupled anti-Fc antibody. C Immunoblot analysis of non-reduced HER3-Fc 
(5 µg per lane) for binding of scFv 3-43. An anti-Fc antibody was included as a positive control. ScFv 
3-43 and HER3-Fc were detected as in (B). 
 
For being able to locate this complex conserved binding epitope of scFv 3-43, the 
extracellular domain of HER3 was subdivided in its four domains and truncated 
versions of HER3-Fc were produced, each lacking one more extracellular domain. 
The truncated versions of HER3-Fc (aa 20-643), namely HER3DII-IV-Fc (aa 208-643), 
HER3DIII-IV-Fc (aa 329-643) and HER3DIV-Fc (aa 532-643), were produced in stably 
transfected HEK293 cells and purified from the supernatant via protein A 
chromatography. SDS-PAGE analysis shown in figure 3-7 A depicts bands in the 
expected size ranges for all constructs. Due to glycosylation, the bands appeared a 
bit smeared or as double bands. These constructs were coated in ELISA plates and 
binding of scFv 3-43 was examined. The experiment revealed that the extracellular 
domain III of HER3 was needed for binding of scFv 3-43, since the scFv bound to all 
constructs comprising this domain. 
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Figure 3-13: Epitope mapping of the 3-43 binding site 
A SDS PAGE analysis under reducing and non-reducing conditions of the full ECD and truncated 
HER3-Fc fusion proteins. Lane 1: HER3-Fc comprising the full HER3 extracellular domain. Line 2: 
HER3DII-IV-Fc lacking the first extracellular domain. Line 3: HER3DIII-IV-Fc lacking the first two 
extracellular domains of HER3. Line 4: HER3DIV-Fc lacking the domains one to three of the HER3 
ECD. B Mapping of the epitope of scFv 3-43 to the four different HER3 extracellular domains was 
performed by ELISA. 10 ng of the full and truncated HER3-ECD-Fc fusion proteins were immobilized 
on ELISA plates. 100 nM of scFv 3-43was applied and detected with HRP coupled anti-His-tag 
antibody. One representative of two independent experiments is shown with mean of double values ± 
SD. 
 
Together with the extracellular domain I of HER3, domain III is involved in ligand 
binding. Binding to this domain therefore can potentially inhibit ligand induced 
signaling pathway activation. To test the ligand dependent signaling inhibiting 
potential of scFv 3-43 and of the second best HER3 binding clone scFv 3-39, MCF-7 
cells were incubated with the HER3 binding scFv proteins or with an irrelevant scFv 
as control for 15 or 60 minutes, followed by a 15 minutes lasting heregulin stimulus. 
Whole cell lysates were substracted to Western blotting and the phosphorylation 
status of HER3, HER2, Akt and the MAPK Erk (isoforms 1 and 2) was analyzed (fig. 
3-8). In the absence of heregulin, HER2, HER3, Akt and Erk(1/2) were hardly 
phosphorylated. Heregulin stimulation induced strong bands for phosphorylated 
HER3, Akt and Erk and a weaker band for phosphorylated HER2. Preincubation with 
scFv 3-43 strongly reduced phosphorylation of HER3, HER2 and Akt. Erk 
phosphorylation could also be reduced, at least after 15 minutes of scFv 
preincubation. The scFv control scFv Gal12 did not reduce heregulin induced protein 
phosphorylation. Preincubation with scFv 3-39 for 60 minutes also reduced HER3 
phosphorylation and phosphorylation of Akt also was reduced through preincubation 
with scFv 3-39. However, heregulin induced Erk phosphorylation could not be 
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prevented by scFv 3-39. This highlighted the suitability of scFv 3-43 for the 
development of a fully human antibody to test its supposable anti-cancer effect. 
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Figure 3-14: scFv 3-43 blocks HRG induced signaling 
A Semi confluent MCF-7 cells were incubated at 37°C with 10 µg/ml scFv 3-43 for 15 minutes or one 
hour before addition of 50 ng/ml heregulin-β. After 15 minutes heregulin stimulation the cells were 
lysed and subjected to immunoblotting with the indicated antibodies. One representative out of three 
independent experiments is shown. B The same experiment like in A was performed using Gal12 
binding scFv as control and the HER3 binding scFv 3-39. 
 
3.6 Dimeric scFv 3-43-Fc 
The scFv protein 3-43 showed high affinity to its cellular expressed antigen HER3. 
However, scFv proteins are very small and unstable. In order to create a dimeric 
protein of higher molecular mass and stability, a scFv-Fc fusion protein was 
established from the respective scFv plasmid. ScFv 3-43-Fc was produced in 
adherent HEK293T cells and purified via protein A chromatography with yields about 
1 mg per liter cell supernatant. ELISA using HER3-Fc and flow cytometry using MCF-
7 cells revealed EC50 values for antigen and cell binding in the low nanomolar range 
(Table 3-5), confirming an avidity effect for dimeric antibody molecules comprising 
the selected binding domains.  
 
Table 3-5: Production yields and binding data of scFv 3-43-Fc  
scFv-Fc yield (in mg|l) 
ELISA 
(EC50 in nM) 
cell binding MCF-7 
(EC50 in nM) 
3-43 1.1 0.8 0.1 
 
The scFv-Fc fusion protein migrated through polyacrylamide during electrophoresis 
with a migration rate fitting to the calculated molecular weight. The double band seen 
in Figure 3-15 A most likely refers to the glycosylated and unglycosylated forms of 
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the fusion protein. However, although the protein looked pure and integer on SDS-
PAGE analysis and bound specifically to its antigen as seen in Figure 3-15 C, size 
exclusion chromatography revealed no exclusive peak (Figure 3-15 B). To get an 
integer antibody with not only high affinity cell binding properties, but also good 
effector functions enabling immune cell recruiting, the VH and VL domains of scFv 3-
43 were in the next part used for generation of IgG1 molecules. 
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Figure 3-15:  Analysis of scFv 3-43-Fc 
A Coomassie stained SDS-PAGE of scFv 3-43-Fc B SEC of scFv 3-43-Fc C ELISA of scFv 3-43-Fc 
using HER3-Fc for coating and HRP-coupled anti-His tag antibody for detection; n=3 ± SD. 
 
3.7 IgG 3-43 
In order to construct a new HER3 binding antibody, scFv 3-43 was converted into a 
human IgG1 (IgG 3-43). To improve ADCC, two amino acid substitutions 
(S239D/I332E) were introduced into the human Fc domain (referred to as SI) as 
described by Horton et al. in 2008151. Approximately 43 mg IgG 3-43 could be 
purified from one liter of supernatant. 
To be able to compare binding and inhibiting properties of IgG 3-43 to a clinically 
tested HER3 targeting antibody, the binding sites of Seribantumab were used for 
cloning of a fully human IgG1 molecule with the same Fc part like IgG 3-43. 
 
3.7.1 Biochemical analysis of IgG 3-43 
The calculated molecular weight of IgG 3-43 accounts to 149.2 kDa. SDS-PAGE 
analysis was performed after purification. IgG 3-43 exhibited one single band under 
non-reducing conditions in the range of approximately 150 kDa, corresponding to the 
antibody dimer. Under reducing conditions, two bands in the range of 50 kDa and 
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25 kDa corresponding to the heavy and light antibody chains were observed. In size 
exclusion chromatography, IgG 3-43 eluted as one single narrow peak. This 
experiment estimated the weight of IgG 3-43 to be 213.6 kDa. The bigger 
hydrodynamic radius presumably accounts to glycosylation. Dynamic light scattering 
revealed a thermal stability of IgG 3-43 up to a temperature of 69 °C. 
 
A 
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Figure 3-16: Biochemical analysis of IgG 3-43 
A Coomassie stained SDS-PAGE analysis of IgG 3-43 under non-reducing (lane 1) and reducing (lane 
2) conditions. B Size exclusion chromatography of IgG 3-43 using a Yarra SEC-2000 column. C The 
thermal stability of IgG 3-43 was analyzed using dynamic light scattering. The measured aggregation 
point was indicated by a dotted line.  
 
3.7.2 Binding property of IgG 3-43 
IgG 3-43 showed dose dependent binding to HER3-Fc in ELISA with an EC50 of 
1.1 nM. Cell binding as measured with the HER3 expressing breast cancer cell lines 
MCF-7 and SKBR-3 revealed EC50 values of 30 pM and 20 pM, respectively. EC50 of 
IgG 3-43 binding to FaDu cells, which express only low levels (about 2900 receptors 
per cell) of HER3, was determined to 3 pM. Compared to IgG 3M6, IgG 3-43 was 
clearly superior with three to six-fold lower EC50 values. IgG 3M6 bound to HER3-Fc 
in ELISA with EC50 of 3.6 nM and to MCF-7 and SKBR-3 cells with 1.1 nM and 
1.2 nM, respectively (not shown).  
 
Table 3-6: Binding of 3-43 and 3M6 antobody constructs 
Construct 
3-43:  
antigen binding 
(EC50 in nM) 
3-43:  
cell binding 
(EC50 in nM) 
3M6:  
antigen binding 
(EC50 in nM) 
3M6:  
cell binding 
(EC50 in nM) 
scFv 1.3 0.6 4.4 3.3 
scFv-Fc 0.8 0.1 NA NA 
IgG1 1.1 0.003 - 0.03 3.6 1.1 - 1.2 
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Figure 3-17: HER3 and cell binding characteristics of IgG 3-43 
A Binding of IgG 3-43 to recombinant HER3 was analyzed by ELISA using HRP coupled Fab-specific 
anti-human IgG antibody for detection of the bound IgG. B, C Binding of IgG 3-43 to cellular HER3 
was analyzed by Flow cytometry using HER3 expressing breast cancer cell lines MCF-7 (B) and 
SKBR-3 (C). Bound IgG was detected using PE conjugated anti-human Fc antibody. D Binding of IgG 
3-43 to FaDu cells was analyzed by Flow cytometry. Bound IgG was detected using PE conjugated 
anti-human Fc antibody. All: n=3, mean values ± SD. 
 
In total, a panel of 12 cell lines was analyzed by flow cytometry for binding of IgG 3-
43. For the human non-cancer cell line HEK 293 and for the ovarian cell line SKOV-
3, which showed the lowest HER3 expression levels of the cells analyzed in chapter 
3.1 (less than 1000 receptors per cell), no binding of 100 pM IgG 3-43 could be 
detected. The human cancer cell lines A431, A549, BT474, Caco-2, Colo 205, FaDu, 
HCT-116, MCF-7, NCI-N87 and SKBR-3 all were specifically bound by IgG 3-43. 
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Figure 3-18: IgG 3-43 binds to numerous human cancer cell lines 
Binding of 100 pM IgG 3-43 was detected via flow cytometry with PE conjugated anti-human Fc 
antibody. Human Embryonic Kidney 293 cells (HEK 293, non-cancer) served as negative control. 
Fluorescence intensities were analyzed using FlowJo software. Black: unstained; grey: detection 
control (anti hu-Fc PE); red: IgG 3-43.  
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In order to get more detailed information about the affinity between IgG 3-43 and 
HER3, quartz crystal microbalance measurements using the Attana system were 
performed. The affinity of HER3-his to IgG 3-43 was determined to 11.2 nM. The 
affinity for the probably bivalent interaction between IgG 3-43 and dimeric HER3-Fc 
was determined to 0.22 nM, highlighting an avidity-strengthened bivalent binding 
characteristic of IgG 3-43. 
 
A 
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Figure 3-19: HER3 binding kinetics of IgG 3-43 
The Attana A200 QCM system was used to analyze the interaction of HER3 and IgG 3-43. All 
measurements were performed at pH7.4. IgG 3-43 was immobilized on a LNB (low non-specific 
binding)-Carboxyl chip. A Two-fold serial dilutions of His-tagged HER3 were injected in random order 
into the Attana QCM system. The starting concentration was 20 nM. B Two-fold serial dilutions of 
HER3 fused to a human IgG Fc part were injected in random order into the Attana QCM system. The 
starting concentration was 10 nM. 
 
Table 3-7: Monovalent and bivalent antigen binding of IgG 3-43 determined by QCM with 
immobilized IgG 3-43 
analyte Bmax ka (M-1s-1) kd (s-1) KD (nM) 
HER3-His 63,55 6,22*105 6,96*10-3 11.2 
HER3-Fc 237,32 4,68*105 1,03*10-4 0.22 
 
3.7.3 Functional characterization of IgG 3-43 
A functional analysis of IgG 3-43s influence on HRG binding, HER pathway activation 
and proliferation of cancer cells was performed in order to monitor possible anti-
cancer effects of the antibody.  
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3.7.3.1 IgG 3-43 blocks HRG binding to HER3 expressing cells and inhibits 
HRG induced ErbB signaling 
Epitope mapping of scFv 3-43 already showed that domain III of the HER3 ECD is 
crucial for the antibody-receptor interaction. Domains I and III of the HER3 ECD are 
known to be involved in ligand binding. Thus, it was of interest whether binding of IgG 
3-43 to HER3 expressing cells prohibits heregulin binding. MCF-7 cells were 
incubated with recombinant his-tagged human heregulin-1 and binding was detected 
via flow cytometry. Preincubation with IgG 3-43 led to a reduction of about 60% of the 
obtained signal intensity, while preincubation with the anti-EGFR antibody cetuximab, 
serving as control, only showed marginal effects on heregulin binding. 
 
 
 
Figure 3-20: IgG 3-43 competes with HRG for binding to HER3 expressing cells 
Binding of His-tagged recombinant human heregulin-β1 (50 nM) in the absence and presence of 
excess of IgG 3-43 (3000 nM) was measured by flow cytometry via PE conjugated anti-His antibody. 
Preincubation of EGFR binding Cetuximab was performed for IgG control. Mean of double values ± 
SD of one representative out of two independent experiments are shown. 
 
Since IgG 3-43 inhibits heregulin binding to HER3 expressing cells, it seems obvious 
that the antibody also may inhibit heregulin induced receptor phosphorylation. Six 
different cell lines were used to study the influence of IgG 3-43 on constitutively 
present and heregulin-induced phosphorylation of EGFR family receptors and 
prominent representative proteins of the downstream signaling pathways. The six cell 
lines, MCF-7, BT-474, NCI-N87, FaDu, A549 and A431 represent not only different 
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cancer types, but also different receptor expression patterns and cancer driving 
mechanisms.  
 
In MCF-7 cells, EGFR phosphorylation could not be detected. HER2 was 
phosphorylated in all samples. HER2 phosphorylation was not significantly affected 
from heregulin stimulation or either antibody. HER3 phosphorylation was detected 
only after heregulin stimulation. IgG 3-43 potently reduced the signal almost to an 
undetectable level. Total HER3 levels also were strongly reduced after IgG 3-43 
incubation. However, HER3 levels seemed slightly weaker as well in the samples 
treated with the control antibody Rituximab. Phosphorylation of Akt was induced by 
heregulin stimulation. This was again strongly inhibited through IgG 3-43. Erk1 and 
Erk2 were already slightly phosphorylated in unstimulated MCF-7 cells. The 
phosphorylation levels were increased after heregulin stimulation and IgG 3-43 
preincubation decreased this heregulin-triggered induction. 
Alike for MCF-7, no influence of heregulin stimulation and IgG 3-43 on 
phosphorylation and expression of EGFR and HER2 could be monitored for the cell 
lines BT-474 and NCI-N87. However, constitutive phosphorylation of the two 
receptors appeared more prominent in NCI-N87. HER3 is constitutively 
phosphorylated in both cell lines. Heregulin induced a powerful increase in HER3 
phosphorylation, which could be reduced to the level of unstimulated cell probes by 
IgG 3-43 preincubation. Akt phosphorylation was also induced by heregulin 
stimulation in both cell lines and this induction was again reduced after preincubation 
of IgG 3-43. Both cell lines showed a moderate constitutive phosphorylation of the 
Erk isoforms 1 and 2. In BT-474 cells, heregulin stimulation induced very strong Erk 
phosphorylation. Here, IgG 3-43 could reduce the signal almost to a basal level. For 
NCI-N87, no influence of IgG 3-43 on Erk phosphorylation was observed.  
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Figure 3-21: IgG 3-43 inhibits HRG mediated signaling in cancer cells 
Indicated cells were seeded in 6 well plates to be semi confluent on the day of experiment. After 
attachment, cells were serum starved overnight and incubated for one hour with 100 nM IgG 3-43 or 
control (Rituximab) IgG or IgG 3-43 in the absence or presence of 50ng/ml human heregulin-β1 
(HRG). Subsequently, cells were lysed with RIPA buffer containing protease inhibitors and cell lysates 
were analyzed by western blot using the indicated antibodies. 
 
With the high EGFR expressing cell lines FaDu, A549 and A431, again, no influence 
of short-time heregulin stimulation and IgG 3-43 on EGFR and HER2 
phosphorylation was observed. The signal intensities of total EGFR as well as 
phospho-EGFR correlated with the EGFR expression level (A431 > FaDu > A549). 
HER3 was constitutively phosphorylated in all three cell lines and signal strength 
ratios were in accordance with the expression analysis data. Heregulin reinforced 
HER3 phosphorylation in all three cell lines and IgG 3-43 potently reduced 
constitutive as well as heregulin induced HER3 phosphorylation. IgG 3-43 also led to 
a reduction of total HER3 levels. Akt phosphorylation was induced by heregulin 
stimulation in A549 and A431. This phosphorylation in turn was inhibited by IgG 3-43. 
Both Erk isoforms were phosphorylated in unstimulated cells to different extend, with 
a very strong constitutive Erk phosphorylation seen in FaDu cells. Here, IgG 3-43 
could reduce the phosphorylation level. Heregulin enforced Erk phosphorylation in 
A549 and FaDu cells, but not in A431. The heregulin induced Erk phosphorylation 
could be inhibited with IgG 3-43. 
 
For all six examined cell lines, 100 nM IgG 3-43 were sufficient to block heregulin 
induced phosphorylation of HER3. To get a better idea of the concentration needed 
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for this blockade, IgG 3-43 was titrated on MCF-7 cells, which were subsequently 
stimulated with heregulin. The levels of phosphorylated and total HER3 were 
analyzed by western blot. 10 nM IgG 3-43 were sufficient to block heregulin induced 
HER3 phosphorylation in MCF-7 cells. The IC50 value of IgG 3-43 was calculated to 
108 ± 36 pM (n=3, ± SD). For IgG 3M6, the IC50 value was 295 ± 139 pM. The total 
HER3 levels were also reduced after incubation of IgG 3-43 in a dose-dependent 
manner. 
 
A  
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Figure 3-22: Low nanomolar concentration of IgG 3-43 is able to block HER3 phosphorylation 
A Semi confluent MCF-7 cells were incubated with the indicated amounts of IgG 3-43 (left) or 3M6 
(right) for one hour before HRG stimulation (50 ng/ml) followed by cell lysis. Levels of phosphorylated 
and total HER3 were analyzed by immunoblotting with the indicated antibodies. One of three 
independent experiments is shown. B Quantification of phospho-HER3 signal; n=2, mean ± SD. 
 
3.7.3.2 IgG 3-43 leads to relocalization of the bound receptor and reduces 
cellular HER3 levels 
Binding of ligands and even some antibodies to their specific receptors may lead to 
internalization of the respective receptor. For example, cetuximab leads to 
internalization and degradation of EGFR152,153. Mechanistically, this could be one 
reason for the inhibition of signaling pathway activation after antibody binding. Thus, 
it is of interest if – and if so, how fast – the respective receptor is internalized and 
degraded. To examine the velocity of and confirm the degradation of HER3 provoked 
by IgG 3-43, MCF-7 cells were incubated for different time periods with IgG 3-43 or a 
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control antibody and HER3 levels were analyzed by western blot. HER3 levels were 
already reduced to less than 50 percent of the original amount after one hour and 
decreased further in the following hours. Incubation with a control antibody showed, 
apart from some fluctuations, no influence on HER3 levels.  
 
A  
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Figure 3-23: IgG 3-43 leads to reduction of cellular HER3 levels. 
Cellular HER3 expression levels after incubation of IgG 3-43 were analyzed by immunoblotting. MCF-
7 cells were incubated with 100 nM IgG 3-43 or control antibody (Atrosab) for the indicated time points 
and then lysed immediately. HER3 levels were analyzed by western blot. The HER3 signal rapidly 
decreased after addition of IgG 3-43, with a reduction already seen after 5 minutes of incubation time. 
A Western blot analysis. One of three independent experiments is shown. B Quantification of HER3 
signal of three independent experiments relative to tubulin loading control and normalized to untreated 
cells (mean ± SD). 
 
In order to create a more detailed view on the fate of the receptor and IgG 3-43 after 
HER3 binding, Cy5 maleimide was coupled to free sulfhydryl groups of the reduced 
antibody. This enabled microscopic examination of the antibody location after defined 
incubation times.  
A Cy5 labeling kit was used to label IgG 3-43 with the fluorescent dye. Labeled 
antibody molecules were purified by permeation chromatography. A yield of 0.8 mg 
labeled IgG was obtained from 1 mg IgG 3-43 used. SDS-PAGE analysis (shown in 
figure Figure 3-24 A) revealed a major band corresponding to the original weight. 
Only, a minor portion of the antibody showed a reduced weight band, indicating that 
a light chain may have been lost during the labeling process. To test the functionality, 
binding to HER3-Fc in ELISA and to MCF-7 cells of Cy5 labeled IgG 3-43 was 
measured and compared to the unlabeled protein. The obtained EC50 values were 
quite identical (IgG 3-43-Cy5 vs IgG 3-43: 0.92 nM vs 0.82 nM in ELISA and 35 pM 
vs 43 pM in FACS analyses), indicating an unimpaired functionality of Cy5 labeled 
IgG 3-43.  
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Figure 3-24: Cy5 coupling of IgG 3-43 
A Coomassie stained SDS-PAGE analysis under reducing (lane 1, 2) and non-reducing (lane 3, 4) 
conditions of IgG 3-43 before (lane 1, 3) and after (lane 2, 4) Cy5 coupling. B Western blot analysis of 
Cy5 coupled IgG 3-43 under reducing (lane 1) and non-reducing (lane 2) conditions using HRP 
coupled anti-human IgG antibody. C Binding of IgG 3-43 or Cy5 coupled IgG 3-43 to HER3 (Fc-fusion) 
was analyzed by ELISA (mean of double values ± SD). D Cell binding of IgG 3-43 before and after 
Cy5 coupling was analyzed by flow cytometry (mean of double values ± SD). 
 
Cy5 labeled IgG 3-43 was then used to study the time-dependent localization of IgG 
3-43. MCF-7 cells, which show a good HER3 expression, were used for this analysis. 
Cy5-labeled IgG 3-43 was added to the cells, which were grown beforehand on 
microscopic slides. The slides were than either let shortly at room temperature or 
incubated for a period of 5 minutes, one hour or two hours at 37 °C. The cells were 
than fixed and stained and analyzed with a fluorescence microscope. 
Without incubation at 37°C, IgG 3-43 was located at the outer part of the membrane 
(Figure 3-25, Figure 3-26). After five minutes of incubation at 37°C, the labeled 
antibody was still located at the membrane, but also a bit at the inner side of the cell. 
After one hour, prominent clusters of labeled antibody appeared inside the cell. After 
two hours of incubation, the main portion of the antibody was located inside the cell. 
Some cy5 signal also appeared again at the outer membrane or even right outside 
the cell. 
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Figure 3-25: Microscopic analysis of IgG 3-43 relocation after binding to MCF-7 cells 
Cy5 labeled IgG 3-43 was incubated with MCF-7 cells at 37 °C for the indicated time periods. Cellular 
membranes were stained with Concanavalin-A and cells were fixed with 4% paraformaldehyde. 
Pictures of treated and control cells were taken with a spinning disk microscope. Blue: Dapi nuclei 
staining; green: Con A membrane staining; red: Cy5-labeled IgG 3-43. Scale bar: 10 µm.  
 
The orthogonal representation of the microscopic pictures shown in figure Figure 
3-26 allows a more precise impression of the location of IgG 3-43 directly after 
addition to MCF-7 or after 5 minutes, 1 hour or 2 hours of incubation at 37°C. The 
sectional planes shown at the image margins clearly identify internalized cy5-labeled 
IgG 3-43 after 37°C incubation. 
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Figure 3-26: Orthogonal representation of microscopic analysis of IgG 3-43 localization 
Cy5 labeled IgG 3-43 was incubated with MCF-7 cells at 37 °C for the indicated time periods. Cellular 
membranes were stained with Concanavalin-A and cells were fixed with 4% paraformaldehyde. 
Pictures of treated and control cells were taken with a spinning disk microscope. Blue: Dapi nuclei 
staining; green: Con A membrane staining; red: Cy5-labeled IgG 3-43. A <1 minute incubation at RT. 
B 5 minutes’ incubation at 37°C C One-hour incubation at 37°C D Two-hour incubation at 37°C. 
 
3.7.3.3 IgG 3-43 is able to reduce cancer cell growth in vitro  
Internalization and degradation of a growth factor receptor, accompanied by inhibition 
of downstream pathway activation, should, in the best case, lead to reduced 
proliferation of cancer cells. The effect of IgG 3-43 on cancer cell proliferation was 
assayed with MCF-7, BT-474, NCI-N87, FaDu and A549. To this end, the cells were 
seeded at low densities in 96 well plates and let grow under low serum conditions in 
the presence of IgG 3-43 or an irrelevant control IgG. After one week of incubation, 
the number of viable cells was measured using a colorimetric assay based on the 
tetrazolium salt WST-8, which is reduced to a formazan dye by dehydrogenase 
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activities in cells. For the two breast cancer cell lines MCF-7 and BT-474 and the 
gastric carcinoma cell line NCI-N87, heregulin dependent proliferation was analyzed. 
Significantly reduced cell numbers after IgG 3-43 incubation compared to the control 
sample were observed for all of the three cell lines. In some cancer types, heregulin 
is produced in an autocrine manner. This mechanism is described for example for 
FaDu and A549. These cell lines were used to study the effect of IgG 3-43 on cancer 
cell proliferation independent from extrinsic heregulin. FaDu cells were incubated 
with serial dilutions of IgG 3-43 or control antibody in reduced serum medium. A 
potent proliferation inhibiting effect of IgG 3-43 was observed at low nanomolar 
concentrations. The IC50 value was calculated to 270 pM. In A549, an about 
20 percent reduced cell number was measured after one-week IgG 3-43 incubation.  
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Figure 3-27: IgG 3-43 decelerates proliferation of various cancer cell lines 
A, B, C: MCF-7 (A), BT-474 (B) or NCI-N87 (C) cells were seeded at low densities in 96 well plates, 
let adhere overnight, and were incubated for one week under low (0,2%) serum concentrations and in 
the presence of 10 ng/ml heregulin with 10 µg/ml IgG 3-43 or Atrosab as control IgG. N=3, mean ± 
SD. D: FaDu cells, known to produce heregulin in an autocrine manner, were subjected to the same 
proliferation assay but in the absence of ambient heregulin. Titration of IgG 3-43 revealed a potent 
growth inhibiting effect even at low nanomolar concentrations. Control: Rituximab. N=3, mean ± SD. E: 
A549 cells were subjected to the same proliferation assay like in D, but as endpoint measurement with 
10 µg/ml IgG 3-43. Control: Atrosab. N=3, mean ± SD. 
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3.7.3.4 In vivo Study of IgG 3-43 
5*106 FaDu cells were injected subcutaneously into both flanks of female immuno-
deficient Fox Chase SCID Beige mice (CB17.Cg-PrkdcscidLystbg-J/Crl). Six mice per 
group received six intravenous injections of 150 µl twice weekly for three weeks on 
days 14, 17, 21, 24, 28 and 31 after cell injection. Whereas the control group 
received only PBS, the three treatment groups received either a total of 30 µg, 
100 µg or 300 µg IgG 3-43 per injection, dissolved in PBS. Figure 3-28 shows the 
group means of tumor volumes. Significant differences in tumor volumes could be 
monitored between the control group and the treated groups. For the IgG 3-43 
treated groups, tumors stopped growing or shrank during the treatment time. 
Approximately two weeks after the treatment ended, the tumors relapsed.  
 
 
Figure 3-28: Intravenous application of IgG 3-43 inhibits growth of FaDu xenografts in immune-
deficient SCID Beige mice 
Mean tumor volumes of the groups. Error bars represent 95% confidence intervals. N=3-6 (6 mice per 
group at start). 
 
Survival of the IgG 3-43 and PBS treated mice was monitored from tumor grafting 
until the end of the study. A Kaplan-Meier blot illustrating the survival curves of the 
differently treated groups is shown in Figure 3-29. Median survival of the groups 
receiving 100 µg IgG 3-43 (59 days) and 300 µg IgG 3-43 (71.5 days) was 
significantly increased compared to the PBS treated group (51.5 days).  
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Figure 3-29: Survival of the xenografted mice 
Kaplan-Meier blot illustrating the survival curves of the differently treated groups. 
 
At day 42, 11 days after the last treatment, mean tumor volumes of all three treated 
groups were significantly lower as the mean tumor volume of the control group 
(Figure 3-30 B). The growth curves of the single tumors shown in Figure 3-30 C-F 
highlight that, despite a relatively high intra-group diversity accounted by a divers 
engraftment of the tumors, tumor growth was delayed for almost all treated animals 
with the longest delay observed for the highest dose.  
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Figure 3-30: Treatment with IgG 3-43 decelerates growth of xenotransplanted FaDu tumors in 
immunosuppressed SCID/beige mice. 
A Tumor volumes and group means before first treatment. Bars indicate mean ± SD. B Tumor 
volumes and group means 11 days after last treatment. Bars indicate mean ± SD C Growth curves of 
single tumors of the PBS placebo treated group. D Growth of single tumors of the six times twice 
weekly 30 µg IgG 3-43 treated group. E Growth of single tumors of the six times twice weekly 100 µg 
IgG 3-43 treated group. F Growth of single tumors of the six times twice weekly 300 µg IgG 3-43 
treated group. 
 
The pharmacokinetic property of IgG 3-43 was assayed during the in vivo study and 
revealed that serum concentrations of IgG 3-43 were higher after the last injection 
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than after the first injection for all three groups, indicating an accumulating dose of 
the antibody. The AUC0-72h values increased approximately 4- to 9-fold. This resulted 
also in increased terminal half-lives, while initial half-lives were not affected (Table 
3-8). 
 
 
Figure 3-31: Pharmacokinetic property of IgG 3-43 
Blood samples of three animals per group were taken at the indicated time points (3 minutes, 1 h, 24 
h, 72 h (and 168 h after the last treatment)). IgG serum concentration was analyzed via ELISA. Mean 
± SD. 
 
Table 3-8: Pharmacokinetic property of IgG 3-43 
amount [µg] application t1/2 α [h] t1/2 β [h] AUC0-72h [nM*h] 
30 µg 
first 11.7 ± 0.8 59.1 ± 28.4 2,366 ± 84 
last 19.7 ± 4.0 87.1 ± 9.9 14,498 ± 873 
100 µg 
first 17.3 ± 5.3 47.8 ± 7.2 22,101 ± 5,882 
last 18.7 ± 3.0 126.5 ± 10.1 62,605 ± 5,046 
300 µg 
first 32.4 ± 9.5 127.9 ± 9.6 151,558 ± 38,462 
last 37.1 ± 9.4 224.2 ± 116.6 610,044 ± 137,488 
 
During the study, the body weight of the mice was measured every other day. No 
treatment related weight loss was observed for all groups, giving a first indication for 
a non-toxic behavior of the antibody.  
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Figure 3-32: IgG 3-43 had no effect on body weight of to SCID beige mice 
Body weight was measured twice weekly. Group means ± SD. 
 
3.7.3.5 No apoptosis induction in FaDu cells after IgG 3-43 incubation 
To adress the question, weather IgG 3-43 can lead to apoptosis induction in FaDu 
cells, as it was indicated in the in vivo study, FaDu cells were incubated for 48 hours 
with IgG 3-43, irrelevant control antibody or single chained TRAIL-Fc fusion protein, 
which is known to induce apoptosis, as positive control. The cells were stained with 
Annexin V and PI and analyzed by flow cytometry. No increased staining was 
detected in the antibody treated cells with the tested concentrations (10 nM, 100 nM 
and 1000 nM) compared to untreated cells after 48 hours.  
 
 
Figure 3-33: Annexin V – PI staining of FaDu cells after 48 hours antibody incubation 
FaDu cells were treated for 48 hours with growth medium containing either 1000 nM Rituximab, 1000 
nM IgG 3-43 or 10 nM IZI1551 (scTRAIL-Fc). Annexin V and PI staining was analyzed with flow 
cytometry. Mean of double values ± SD. 
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3.7.3.6 Presence of IgG 3-43 partially restores lumen formation in oncogenic K-
RasG12V expressing Caco-2 cells 
The hitherto obtained data document the suitability of IgG 3-43 for inhibition of HER3 
downstream signaling and thereby of cancer cell proliferation. A proliferation 
inhibiting effect could also be observed in BT-474 and MCF-7 cells, which carry a 
mutation in the gene encoding for PI3K. In A549, which carry a mutated form of K-
Ras, a partial inhibition of proliferation could also be achieved with IgG 3-43. For an 
application as anti-cancer drug, it is of great interest, weather IgG 3-43 cannot only 
decelerate proliferation, but also is able to reduce or reverse other carcinogenic 
characteristics, like aberrant morphogenesis induced by dedifferentiation of the cells. 
A 3D model of Caco-2 cells with inducible expression of oncogenic K-RasG12V was 
used to study the influence of IgG 3-43 on K-RasG12V driven aberrant morphogenesis 
in cysts formed by Caco-2 cells in matrigel. The cells harbor a doxycycline (dox)-
regulated expression system, described by Herr et al. 2011154, allowing the 
conditional expression of K-RasG12V. AZD8931, a pan HER inhibitor (inhibiting 
signaling by EGFR, HER2 and HER3), was used as positive control for a partial 
reversion of the aberrant morphogenic phenotype and Rituximab served as IgG 
control. Doxycycline induced K-RasG12V expression is accompanied by expression of 
GFP. WT K-Ras expressing cells formed round cysts with cell free lumen and F-actin 
staining of the apical surface. K-RasG12V expression induced an aberrant phenotype 
with no cell free lumen or multiple lumens and divergent cell numbers. The ‘normal’ 
form with one single apical lumen could be restored in some cysts by addition of 
AZD8931. IgG 3-43 also led to phenotype rescue for a significant number of cysts. 
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Figure 3-34: IgG 3-43 restores aberrant 
morphogenesis of Caco-2 K-RasG12V cells 
in 3D culture 
A Microscopic Images of Cysts formed by 
Caco-2 cells in Matrigel. Caco-2tet K-
RasG12V cells were seeded into 3D cultures 
in the absence or presence of dox. Three 
days’ post seeding lumen expansion was 
induced by CTX. Cultures were fixed two 
days later and stained with DAPI (nuclei; 
blue) and phalloidin (F-actin; red). GFP is 
co-expressed with K-RasG12V (green). 
Shown are confocal sections of the 
midplane of representative cysts. Scale bar: 
20 µm. B The percentage of cysts with one 
single apical lumen was determined (n>70, 
N=3, mean ± SD). 
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4 Discussion 
In this work, fully human IgG molecules with ADCC strengthening constant regions 
were generated for therapeutic applications. The variable regions were selected from 
a panel of phage display derived scFv proteins. In one part of the study, HER2 
binding IgG 2-35 was generated and analyzed. A strong avidity effect could be 
achieved with the bivalent IgG format, leading to a three point five times reduced 
EC50 value for cell binding. IgG 2-35 reduced proliferation of HER2 overexpressing 
NCI-N87 ant BT-474 cells. In the other part of the study, HER3 binding IgG 3-43 was 
generated. IgG 3-43 was shown to bind to domain III of HER3, thereby impeding 
heregulin binding, leading to reduced heregulin induced as well as constitutive HER3 
and Akt phosphorylation. IgG 3-43 furthermore was internalized into MCF-7 cells and 
reduced cellular HER3 levels. Most importantly, antitumor activity of IgG 3-43 
including tumor regression during the treatment phase and a prolonged survival was 
demonstrated in a subcutaneous FaDu xenograft tumor model in SCID mice. 
4.1 Selection of scFv proteins 
The scFv proteins analyzed in this study were selected from the naïve antibody gene 
libraries HAL7 and HAL8155 by phage display prior to this thesis. Phage display 
derived antibodies comprise several advantages compared to more classic 
techniques such as in vivo immunization or infection156. Antibodies generated by 
immunization of a non-human host usually are more immunogenic than a human-
derived antibody, even after humanization by replacement of constant or framework 
regions with human equivalents157. Immunogenicity can lead to increased toxicity and 
reduced clinical efficacy158. Furthermore, the technique allows facile post-
optimization processes, like affinity maturation159.  
4.2 HER2 
HER2 frequently is amplified in human tumors, especially in breast carcinoma160, and 
increased expression of the receptor results in cellular transformation and 
tuzmorigenesis161. Since the intracellular kinase domain of HER2 as well is more 
active than that of EGFR162, HER2 targeted antibody therapy has great potential, 
especially for HER2 overexpressing tumors163. The first biological drug approved for 
the treatment of HER2-positive breast cancer, trastuzumab, remains the gold 
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standard for treatment of this disease164. However, about 60% of patients with HER2 
positive breast cancer develop de novo resistance to trastuzumab, partially due to 
the loss of expression of HER2 extracellular domain on their tumor cells due to HER2 
cleavage by metalloproteinases (ADAMs and MMPs)165. Recent research in breast 
cancer therapy has therefore focused on dual blockade of HER2, combining 
trastuzumab and lapatinib or trastuzumab and pertuzumab, or simultaneous blocking 
of other pathways166, and more HER2 targeting antibodies with cytostatic effects on 
tumor cells will enrich the possibility spectrum for combination and monotherapy and 
possibly broaden the understanding or eventually circumvent resistance 
mechanisms.  
4.2.1 IgG 2-35 shows good binding, but inconsistent inhibiting 
properties 
Affinity measurements against HER2-Fc revealed a KD of 24.8 nM for scFv 2-35, 
which is about 20 times weaker than scFv 4D5, the scFv comprising the binding site 
of the clinically approved Trastuzumab, herein showing a KD of 1.2 nM. Affinity 
maturation, which also can be performed by phage display, could increase the affinity 
of the 2-35 variable domains167. Importantly, scFv 2-35 did not compete with 
trastuzumab for HER2 binding, which is favorable for a possible combination or the 
generation of bi- or multi-specific antibody constructs, a strategy proven to be 
meaningful in the past. Tóth et al. demonstrated in 2016 that the combination of 
trastuzumab (binding to the juxtamembrane region of HER224) and pertuzumab 
(binding to domain II of HER2106) slowed tumor growth of xenografts from intrinsically 
trastuzumab-resistant JIMT-1 cells168. Pedersen et al. demonstrated a synergistic 
antitumor activity of a tripartite antibody mixture targeting HER2 subdomains I, II, and 
IV that was superior to trastuzumab in vitro169. A triparatopic Tribody consisting of 3 
noncompeting ErbB2 binders designed by Riccio et al. was more efficient in 
downregulating ErbB2 and inhibiting tumor cell growth than the control 
monoparatope tribodies or the combinatorial treatment with the 3 different parental 
antibodies on tumor cells170.  
IgG 2-35 bound to recombinant HER2 and HER2 expressing cells with EC50 values 
slightly lower than these of trastuzumab, with EC50 values for IgG 2-35 of 200 -
300 pM and for trastuzumab of 0.5 – 2.5 nM for cell binding. The binding property of 
IgG 2-35 was about 3.5 times enhanced compared to the scFv, indicating a strong 
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avidity effect. In contrast, series of human IgG1 isotype antibodies created from the 
anti-HER2 C6.5 scFv and its affinity mutants retained the affinities of the scFv from 
which they were derived171. For some anti-EGFR antibodies however, bivalent IgG 
also had higher observed binding affinity than the cognate monovalent constructs172. 
It is in accordance with literature, that the low affinity scFv 2-35 could benefit more 
from avidity effects in the IgG format than the trastuzumab derived scFv 4D5, since a 
work of Nielson et al. indicated that the affinity gain upon conversion from the 
monovalent to the bivalent format is higher for low affinity binders173. 
In the gastric cancer cell line NCI-N87 and the breast cancer cell line BT-474, IgG 2-
35 inhibited proliferation in the presence of EGF with an about 20 percent enhanced 
effect compared to trastuzumab. The experiments confirm that, although the scFv 
affinity of 2-35 was inferior to that of trastuzumab, as IgG the antibody is superior to 
trastuzumab in this setting. Inhibition of EGF induced proliferation with HER2 
targeting antibodies is in good accordance to literature, since it was found already in 
the 90s that HER2 is a potentiator of the EGF signal174,175 and kinase-deficient HER2 
suppresses EGFR function176. Interestingly, IgG 2-35 did not inhibit proliferation of 
SKBR-3 cells in normal growth medium which, however, was observed in the case of 
trastuzumab. The growth inhibiting effect on SKBR-3 cells was also shown by others 
for the mouse precursor of trastuzumab 4D5102. However, 4D5 did not have any 
growth inhibiting effect on the mammary carcinoma cell lines MCF-7, MDA-MB-157 
and MDA-MB-231, but also on MDA-MB-361 and MDA-MB-175-VII, which express 
high levels of HER2177. In conclusion, IgG 2-35 does not stand alone in provoking 
diverging effects in different cell lines. 
More efforts have to be made to elucidate the mode of function of IgG 2-35. No 
blockade of HER receptor phosphorylation could be shown in MCF-7 cells with 
IgG 2-35. This suggests, that IgG 2-35 is no potent inhibitor of HER2 dimerization. 
Epitope mapping of IgG 2-35 was performed by Jonas Honer in his Master thesis178 
in order to better understand the effects mediated by the antibody. This experiment 
showed that the epitope of IgG 2-35 is located on domain I of the HER2-ECD, and 
maybe incorporates parts of domain II. This epitope localization makes a potent and 
full inhibition of dimerization unlikely. The clinically approved Pertuzumab stericallly 
blocks HER2 dimerization and signaling by binding to ErbB2 near the center of 
domain II106, the RTK domain incorporating the dimerization arm179. 
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Another possible way to influence cellular processes, such as proliferation, is 
receptor down-regulation through internalization and degradation169. Down-
modulation of the targeted receptor is one of the phenotypic changes observed in 
vitro as an effect of trastuzumab180. A reduction of HER2 surface levels may be more 
effective in a setting, where stimulating ligands are available and HER2 could 
contribute to more efficient signaling dimers. Further studies are necessary to 
examine the mechanism by which IgG 2-35 inhibits proliferation of HER2 expressing 
cancer cells and to elucidate predictive biomarkers for a cellular response. The 
inhibition of EGF driven proliferation in NCI-N87 and BT-474 cells hints on an anti-
tumor activity of the antibody. Anyhow, IgG 2-35 may also be suited for the use as 
targeting unit of antibody drug conjugates or in bispecific antibodies or combinatory 
settings. Trastuzumab-DM1 for example shows greater anti-proliferative activity 
compared to unconjugated trastuzumab while maintaining selectivity for HER2-
overexpressing tumor cells181.  
4.2.2 Inadequate integrity of scFv-Fc fusion proteins 
ScFv-Fc fusion proteins were constructed in order to get bivalent antibody proteins. 
Although the purity of the proteins seemed adequate in SDS-PAGE analysis, size 
exclusion chromatography revealed a poor integrity. In contrast, this format showed 
good integrity in former studies (see e.g. Unverdorben et al. 2016182). However, the 
proteins analyzed in the mentioned studies comprise a different scFv linker, namely 
(G4S)x3, whereas the linkers of the herein analyzed scFv proteins, which also 
connect the heavy and light variable chains in the scFv-Fc fusions, consist of the 18 
amino acids GSASAPKLEEGEFSEARV. This may be one reason for the different 
protein integrities.  
4.3 HER3 
Similar to HER2, HER3 is also often expressed in breast cancer in an elevated 
manner183, playing an important role in cancer progression and chemotherapy 
resistance184. ScFv3-43 was chosen for conversion to the IgG format and further 
development due to potent receptor binding and efficient inhibition of heregulin-
induced HER3 phosphorylation. As heregulin induced signaling pathway activation is 
implicated in cancer growth and progression as well as in resistance to different anti-
cancer drugs185, this characteristic is highly desirable.  
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4.3.1 Distinguished binding characteristics of IgG 3-43 
ScFv 3-43 was primarily chosen for further expression as fully human IgG1 antibody 
for its good cell binding characteristics. The monovalent antibody molecule bound to 
cellular HER3 with an EC50 value of around 600 pM. Anyhow, it could not be 
excluded that scFv 3-43 forms dimers, as the estimated corresponding molecular 
mass of 38.7 kDa for the scFv interpolated after size exclusion chromatography from 
the protein standard is bigger than the calculated molecular mass of 31,1 kDa. Cell 
binding was six times enhanced through expression of the antibody’s binding sites in 
a bivalent molecule by –Fc fusion, hinting on a potent avidity effect. The IgG format 
further enforced the binding strength, what accounted to a 20 times stronger cell 
binding compared to the scFv. This increase magnitude in binding strength seems to 
be format specific, because neither the expression as scFv-Fc nor as scDb led to 
EC50 values in the same range as the IgG. Even a tetravalent scDb-Fc fusion 
molecule bound to FaDu cells with an EC50 value of 180 pM, whereas IgG 3-43 
bound in the same setting with an EC50 value of 6 pM178. An approximate 10- to 100-
fold increase in binding through avidity effects is in accordance with data obtained for 
anti-EGFR antibodies with affinities in the nanomolar range172. 
The differences seen between antigen binding in ELISA and cell binding may be due 
to different antigen densities, as well as different receptor surrounding on cells and 
different conformation. The antigen binding properties are comparable for all formats, 
whereas they differ strongly in terms of cell binding. In ELISA, through the high 
antigen density, monovalent binding is reflected, whereas in cell binding also format 
specific advantages are reflected. Affinity measurements using quartz crystal 
microbalance depicted a KD of the monovalent his-tagged receptor to IgG 3-43 in a 
range comparable to the EC50 values detected for binding of the 3-43 binding site to 
the receptor. The bivalent HER3-Fc had a higher affinity to the immobilized IgG 3-43. 
Here, the KD lay at 220 pM, being more comparable to the bivalent cell binding of the 
3-43 constructs. However, cell binding of IgG 3-43 seems to be still stronger. In the 
QCM setting, IgG 3-43 was immobilized. It may be that the antibody needs its full 
flexibility to access its complete binding strength.  
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4.3.2 Mechanistic considerations of IgG 3-43’s impact on cancer 
cell signaling 
The effect of a receptor-targeting antibody is to a huge extent determined by its 
epitope, as binding to different epitopes may lead to divers results. Depending on the 
bound epitope, antibodies can for example exert conformational effects, such as 
fixating the receptor in a certain conformation, which in turn can determine the 
activation status113. Inhibition of receptor dimerization through binding at or near the 
dimerization arm is another possibility to influence receptor activity186. Furthermore, 
binding near the ligand-binding pocket can prevent binding of the natural ligand110. 
The epitope of scFv 3-43 was mapped in this study to domain III of the HER3-ECD. 
However, further analyses conducted later by Alexander Rau and Jonas Honer 
defined the epitope more precisely to be located on a fragment formed by aa 329 - 
587, containing the entire domain III and 56 amino acids from the N-terminal region 
of domain IV187. To identify the exact epitope of IgG 3-43, further studies, for example 
using mutational scanning or structural analyses, are necessary. Structural analyses 
like crystallographic studies would be of advantage though the complex epitope is 
sensitive to chemical reduction, which complicates easy mapping strategies such as 
using peptide microarrays or ELISpot techniques. 
In this study it was shown that IgG 3-43 binds to domain III of HER3, although, 
meanwhile, it was pointed out that a small part at the N-Terminal region of domain IV 
of HER3 also contributes to the epitope. By binding to this receptor area, IgG 3-43 
potently prevents ligand binding and thereby also phosphorylation of the receptor. 
So, the first mode of action of IgG 3-43 is to prevent ligand dependent HER pathway 
signaling through prevention of ligand binding. This already can inhibit several cancer 
driving processes through downregulation of two important signaling pathways, the 
PI3K/Akt and the (Ras – Raf – MEK – Erk) MAPK pathway. 
The second effect of the antibody is internalization and degradation of the bound 
receptor, leading to reduced HER3 receptor levels. Basal HER3 turnover is 
negatively regulated by the E3 ubiquitin ligases NEDD4188 and Nrdp1189. Antibody 
induced receptor internalization and degradation was already described for other 
antibodies. For example, Jaramillo et al. could show that treatment with cetuximab 
results in a 30-40% decrease in surface EGFR152. The same group also showed that 
endocytosis of the antibody occurred and that it is recycled to the surface152. In the in 
vivo study, accumulation of the doses was observed, despite antigen presence as 
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well in the FaDu tumors as in healthy tissues of the mice190. The mechanism of 
cetuximab mediated EGFR down-regulation was examined by Dai et al, who found 
that cetuximab modulates EGFR protein stability through the ubiquitin/proteasome 
pathway in human oral squamous cell carcinoma cells153. However, HER3 
degradation induced by IgG 3-43 appears to be much faster than EGFR degradation 
induced by cetuximab. Besides the biologic differences of the receptors, a possible 
explanation for the differing internalization velocities, are the distinct differences 
between the affinities with which the antibodies and the natural ligands bind the 
receptors. Cetuximab binds to EGFR with a KD of 200 pM107,191, whereas TGF-α 
binds EGFR with a similar affinity of 1 nM107. The affinity difference between IgG 3-43 
and heregulin (KD=1.9 nM192) are more pronounced. The antibody 9F7-F11, which is 
directed against domain I of HER3 and also induces rapid internalization of the 
receptor123, recently was shown to induce HER3 down-regulation through 
ubiquitinylation and degradation driven by the itchy E3 ubiquitin ligase (ITCH/AIP4) in 
a JNK1/2-dependent manner193. 
Another potential mechanism, by which growth factor receptor binding antibodies can 
alter cellular functions, is by influencing the conformation of the receptor. Cetuximab 
binds to domain III of the EGFR-ECD. An X-ray crystal structure of the antigen 
binding (Fab) fragment from cetuximab, in complex with the soluble extracellular 
region of EGFR, showed that cetuximab interacts exclusively with domain III of 
sEGFR23. The crystal structure was published by Li et al., who also stated that 
cetuximab thereby partially occludes the ligand binding-region on this domain and 
also sterically prevents the receptor from adopting the extended conformation. The 
extended conformation is in turn needed for dimerization. As the extracellular domain 
of HER3 is to about 40-50% identical with that of EGFR194,195, and regarding that the 
epitope of IgG 3-43 is also located on domain III of its receptor, a similar steric 
blockade is possible. For KTN3379, a HER3 binding antagonistic monoclonal 
antibody that is currently in clinical development in human cancer patients, a 
conformation blocking binding mode is highlighted through a crystal structure of the 
Fab fragment, in complex with the extracellular domain of HER3113. Here, 
extracellular domains III and II of HER3 contribute to the epitope. Weather IgG 3-43 
also infers with receptor dimerization, either through a prevention of the extended 
conformation or through other steric interferences, could be further examined by 
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crystal structure analyses of the IgG 3-43 Fab fragment in complex with the HER3 
extracellular region.  
 
 
Figure 4-1: Mechanism of IgG 3-43’s effect on HER3  
IgG 3-43 leads to reduced levels of cellular HER3 and inhibits HRG binding. Impacts on HER3 
conformation and dimerization are to prove.  
 
No apoptosis induction of HER3 expressing cells could be seen in vitro in 2D with 
IgG 3-43 after 48 hours. Nonetheless, the size reduction of FaDu tumors seen in the 
in vivo experiment may indicate an apoptosis inducing effect of 3-43 in vivo. 
Apoptosis induction has been described for some anti-HER3 antibodies123, whereas 
Seribantumab did not induce apoptosis on its own but enhanced apoptosis induced 
by chemotherapeutic drugs196. Instead of direct apoptosis induction, inhibition of 
angiogenesis through receptor cross talk may lead to IgG 3-43-triggered tumor cell 
death in vivo. Since the expression and secretion of VEGF in breast cancer cells is 
regulated by heregulin197, angiogenesis inhibition with a HER3 targeting antibody is 
in accordance with current knowledge. The role of HER3 in angiogenesis was further 
supported by Yu et al. in 2011 who showed that miR-148a inhibits tumor 
angiogenesis through downregulation of HER3 and resulting reduced activation of 
downstream signaling molecules198. Tissue analysis of treated tumors could provide 
more hints untangling this issue. 
4.3.3 IgG 3-43 potently inhibits cancer cell proliferation and seems 
applicable as anti-cancer drug 
In this study, it was shown that IgG 3-43 inhibits heregulin binding to HER3 
expressing cells, downregulates cellular HER3 levels through antibody mediated 
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receptor internalization and, most importantly, leads to reduced proliferation of 
multiple human cancer cell lines. Reduced proliferation was monitored in heregulin 
dependent settings, as well as in heregulin independent settings. This is of special 
importance, as in some cancers autocrine heregulin loops exist98,199. Expression of 
heregulin by the cancer cells is an often observed resistance mechanism implicated 
in resistance to other HER receptor targeting drugs, for example cetuximab200 or 
trastuzumab200-202. Ebbing et al. lately demonstrated with esophageal cancer cells 
that upregulation of HER3 is the most important response of HER2 inhibition with 
trastuzumab, that was accompanied with HER2 decrease. The group furthermore 
showed that HER3 mediated trastuzumab resistance was dependent on autocrine 
NRG-β shed by upregulated ADAM10201. 
In the in vivo study, a long serum availability of IgG 3-43 was observed, fulfilling 
already one desired drug characteristic of long bioavailability203. The magnitude of 
the time-period of availability in the body can influence drug responses. In a study 
dealing with infliximab treatment of rheumatoid arthritis, low infliximab serum levels at 
an early stage often were associated with treatment failure204. Furthermore, no loss 
of body weight was observed in the in vivo study, indicating good tolerability of the 
antibody. IgG1 molecules are well approved for clinical use. However, a more precise 
examination of IgG 3-43 tolerability might be advantageous. Importantly, a size 
reduction of FaDu xenografts treated with IgG 3-43 was demonstrated in the in vivo 
study. During the treatment period, tumor outgrowth was prohibited for all mice 
receiving 300 µg IgG 3-43 q2w3. The median half-life of the tumor bearing mice was 
prolonged about 20 days for the group twice weekly receiving 300 µg IgG 3-43 
compared to the PBS group. This prolongation is in good correlation to the time span 
of the treatment period, indicating that IgG 3-43 is able to protect from tumor 
expansion in a dose-dependent manner. 
Moreover, immune effector cells might contribute to antitumor activity. This was 
shown for the glycoengineered anti-HER3 antibody RG7116 in an orthotopic lung 
xenograft model of A549 cells in SCID mice116. Antibody-dependent cellular 
cytotoxicity is believed to be a major antitumor mechanism of some cancer cell 
targeting antibodies171. For IgG 3-43, ADCC was demonstrated in vitro with SKBR3 
cells and natural killer cell-containing human PBMCs187. Here, efficient lysis of tumor 
cells was observed with an EC50 value of 2.4 pM. Compared to IgG 3M6, (also 
comprising the two mutations (S239D/I332E) in the Fc region to enhance ADCC), 
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which is derived from Seribantumab, an approximately four-fold stronger ADCC was 
determined. This could be explained by the higher affinity to HER3 observed for IgG 
3-43, since antibody to target affinity was shown by Tang et al. to be a factor 
influencing ADCC171. 
4.3.4 IgG 3-43 in comparison with other available antibodies 
Since it became clear that HER3 might be a promising target for anti-cancer therapy, 
many HER3 binding antibodies were developed. Over 40 different HER3-targeting 
agents already are under development15. More than half of them are monospecific 
antibodies in different developmental stages, rising from preclinical up to clinical 
Phase 3. To judge the usefulness of another new HER3 targeting agent, a 
comparison with other antibodies in the pipeline is relevant. For none of the HER3 
targeting monovalent antibodies that already entered in clinical studies, an epitope to 
that domain III and IV of HER3 contribute is reported15, highlighting a unique 
characteristic of IgG 3-43. This also offers a good opportunity for dual HER3 
targeting. Dual targeting of one receptor can be beneficial in some cases. For IGF-1R 
it was shown that antibodies recognizing different epitopes of the receptor exhibit an 
increased neutralizing potential205. Phillips et al. confirmed in 2014, that dual 
targeting with the antibody-drug conjugate trastuzumab ematisine (T-DM1) and 
pertuzumab results in enhanced antitumor activity in models of HER2-amplified 
cancer206. In respect to binding affinities, IgG 3-43 ranks amongst the best binding 
candidates under development. Concerning the Fc region, IgG 3-43 includes two 
mutations (SI) for improved ADCC151. Other HER3 targeting antibodies also 
incorporate modifications to enhance ADCC. The Fc-region of Lumretuzumab has 
been glycoengineered to increase the affinity toward the Fc-gamma receptor (Fcγ 
RIIIa) on immune effector cells116. 
 
From the mechanistic view, other antibodies are known to provoke similar cellular 
effects like IgG 3-43. Seribantumab110 and Lumretuzumab116 also prevent heregulin 
binding to the receptor, inhibiting HER3 phosphorylation. Patritumab and 
Lumretuzumab also lead to downregulation of HER3. In the case of Patritumab, this 
was also linked to receptor internalization. The antitumor effect of IgG 3-43 seen in 
the FaDu xenograft model is in line with literature. LJM716 has been demonstrated to 
have tumor regression efficacy in vivo against the ligand driven model115. U3-1287 on 
the other hand only partially inhibited growth of these tumor cells207. In the present 
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study, the 3-43 binding site was in many analyses compared to the binding site of 
Seribantumab (MM-121) which showed anti-proliferative effects in in vivo studies with 
several xenografts due to the competition with HRG for HER3 binding, as well as the 
ability to downregulate HER3 from the cell surface, depending on cancer cell line111. 
4.4 Summary and Outlook 
In this study, two ErbB receptor-binding antibodies with high affinities to their 
antigens and antigen-expressing cells were generated. IgG 2-35 inhibits proliferation 
of HER2 overexpressing BT-474 and NCI-N87 cells. More in vitro and in vivo 
analyses are necessary, to elucidate the effect of IgG 2-35 on HER2 positive cancer 
cells and to evaluate its anti-tumor activity. ADCC could lead to potent anti-tumor 
effects of IgG 2-35 and should be addressed in further studies. For trastuzumab, in 
vitro studies have demonstrated effective antibody-dependent cell-mediated 
cytotoxicity against HER2-overexpressing tumor targets180. The high affinity in 
combination with the ADCC enhancing mutation of the constant region, make IgG 2-
35 an interesting candidate for targeted therapy of HER2 positive cancer. 
Furthermore, the variable domains of IgG 2-35 offer a potent binding module for the 
use in Bispecific antibody molecules. 
 
In the main part of this study, a fully human monoclonal IgG1 antibody with 
engineered Fc part in order to promote enhanced ADCC and high affine, avidity 
strengthened binding to HER3 was established. The antibody was characterized in 
terms of antigen and cell binding, impact on HRG dependent and HRG independent 
signaling, and cancer cell proliferation. An excellently high affinity to the dimeric 
receptor of 220 pM and outstanding cell binding with EC50 values between 3 and 
30 pM are reported. Mechanistically, it was shown that IgG 3-43 leads to a fast 
degradation of cellular HER3 and is internalized into the cells. First experiments 
indicating a rescue from oncogenic K-Ras driven transformation were collected. 
These experiments strengthen the hypothesis postulated by Möller et al. (2016)208, 
that the cancer driving force of oncogenic K-Ras depends, at least partially, on its 
role in the formation of an autocrine heregulin loop.  
The growth reduction of FaDu xenografts observed in the in vivo study in this thesis 
resulted from the growth inhibiting effect of IgG 3-43. To monitor also the immune 
stimulating effect of the antibody, a syngenic mouse tumor model, such as the 4T1 
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model, can be used209,210. By applying immune-competent mice, the two anti-
tumorigenic mechanisms, growth inhibition and immune cell targeting and 
stimulation, can be studied, which may lead to even stronger effects. Crosstalk 
between mouse effector cells and human IgG1 Fc-part will in this case trigger ADCC, 
as described by Overdijk et al. (2012)209. As the herein performed in vitro 
experiments implicate a potent inhibiting effect of IgG 3-43 on cancer cell growth 
driven by HER2 overexpression, another in vivo study for example using xenografts 
formed by N87 gastric cancer cells could be performed. For the anti HER3 antibody 
KTN3379, Lee et al. could show significant tumor growth reduction in nu/nu athymic 
mice using the N87 model113. HER3 is also postulated to be a potential target in the 
treatment of gastric cancer211. More in vitro and in vivo studies can examine the use 
of IgG 3-43 in this cancer type. Furthermore, due to the role of HER3 in resistance to 
other ErbB member targeting therapies201,212,213, combination studies using for 
example trastuzumab or cetuximab resistant models would be interesting214,215. 
Generally, combination of IgG 3-43 with TKIs or other monoclonal antibodies as well 
as the of bispecific antibodies incorporating the 3-43 binding site would be a 
promising strategy for the treatment of various cancer types, like HER2 
overexpressing gynecological cancers216, colon cancer217, lung218 and head and neck 
cancer219. As HER3 expression correlates with reduced survival of melanoma 
patients91, the use of IgG 3-43 in combination with TKI in melanoma may also lead to 
improved treatment outcomes. A preclinical proof of concept for the application of 
HER3-targeting antibodies to enhance the efficacy of RAF inhibitors in melanoma 
was offered by Kugel et al. in 2014220. Furthermore, combination of the antibody with 
cytostatic or cytotoxic drugs in one molecule may be a powerful strategy, supported 
by the high affine binding capacity of 3-43 as well as the induced fast receptor 
internalization221. In this case, because of the internalization of 3-43, application of 
intracellular active drugs is possible. However, due to the relatively low HER3 surface 
expression of many cancer cells, it would be beneficial to combine the antibody with 
another tumor-selective drug, like for example TRAIL222,223.  
Taken together, a novel human anti-HER3 antibody with the ability for inhibiting 
heregulin-dependent and ligand-independent receptor activation, downstream 
signaling and cell proliferation was established in this study, which is a promising 
candidate for the treatment of various cancer types. 
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